The Gary Null Show - 10.21.21

Dr. John Campbell is a Senior Lecturer in Nursing studies at the University of Cumbria. He has been a clinical nurse and a nurse tutor for over 30 years. In addition to writing books, he has also produced a range of videos and podcasts on various health and nursing related topics. As well as selling his materials in the Western countries, many are distributed at no cost, or low cost, to students in poorer countries

Dr. Wolfgang Wodarg | Full Interview | Planetlockdown. October 18, 2021. In this intimate sit down interview with Wolfgang Wodarg, we discuss the broad issue of corruption in the WHO, how we should understand the "pandemic," or lack there of and how we must stop this diabolical trend towards a fake medical dystopia that will take over all aspects of our lives. He is one of the most honest and thoughtful people we have ever met and has an amazing resume and has lived a rich life full of experiences that uniquely qualifies him to understand the depth and breadth of this complex situation we find ourselves in.

The Gary Null Show - 10.20.21

Eating leafy greens could help prevent macular degeneration

Westmead Institute for Medical Research (Australia), October 13, 2021 

A new study has shown that eating vegetable nitrates, found mainly in green leafy vegetables and beetroot, could help reduce your risk of developing early-stage age-related macular degeneration (AMD).

Researchers at the Westmead Institute for Medical Research interviewed more than 2,000 Australian adults aged over 49 and followed them over a 15-year period.

The research showed that people who ate between 100 to 142 mgs of vegetable nitrates each day had a 35% lower risk of developing early AMD than people who ate less than 69mgs of vegetable nitrates each day.

Lead Researcher Associate Professor Bamini Gopinath from the Westmead Institute and the University of Sydney said the link between vegetable nitrates and macular degeneration could have important implications.

"This is the first time the effects of dietary nitrates on macular degeneration risk has been measured.

"Essentially we found that people who ate 100 to 142 mgs of vegetable nitrates every day had a reduced risk of developing early signs of macular degeneration compared with people who ate fewer nitrates.

"If our findings are confirmed, incorporating a range of foods rich in dietary nitrates - like green leafy vegetables and beetroot - could be a simple strategy to reduce the risk of early macular degeneration," Associate Professor Gopinath said.

Spinach has approximately 20mg of nitrate per 100g, while beetroot has nearly 15mg of nitrate per 100g.

The research did not show any additional benefits for people who exceeded 142mgs of dietary nitrate each day. It also did not show any significant connections between vegetable nitrates and late stage AMD, or between non-vegetable nitrates and AMD risk.

One in seven Australians over 50 have some signs of macular degeneration.

Age is the strongest known risk factor and the disease is more likely to occur after the age of 50.

There is currently no cure for the disease.

The research compiled data from the Blue Mountains Eye Study, a benchmark population-based study that started in 1992.

It is one of the world's largest epidemiology studies, measuring diet and lifestyle factors against health outcomes and a range of chronic diseases.

"Our research aims to understand why eye diseases occur, as well as the genetic and environmental conditions that may threaten vision," Associate Professor Gopinath concluded.

Research review shows intermittent fasting works for weight loss, health changes

University of Illinois Chicago, October 13, 2021

Intermittent fasting can produce clinically significant weight loss as well as improve metabolic health in individuals with obesity, according to a new study review led by University of Illinois Chicago researchers.

"We noted that intermittent fasting is not better than regular dieting; both produce the same amount of weight loss and similar changes in blood pressure, cholesterol and inflammation," said Krista Varady, professor of nutrition at the UIC College of Applied Health Sciences and author of "Cardiometabolic Benefits of Intermittent Fasting." 

According to the analysis published in the Annual Review of Nutrition, all forms of fasting reviewed produced mild to moderate weight loss, 1 percent to 8 percent from baseline weight, which represents results that are similar to that of more traditional, calorie-restrictive diets. Intermittent fasting regimens may also benefit health by decreasing blood pressure and insulin resistance, and in some cases, cholesterol and triglyceride levels are also lowered. Other health benefits, such as improved appetite regulation and positive changes in the gut microbiome, have also been demonstrated. 

The review looked at over 25 research studies involving three types of intermittent fasting: 

• Alternate day fasting, which typically involves a feast day alternated with a fast day where 500 calories are consumed in one meal. 
• 5:2 diet, a modified version of alternate day fasting that involves five feast days and two fast days per week. 
• Time-restricted eating, which confines eating to a specified number of hours per day, usually four to 10 hours, with no calorie restrictions during the eating period. 

Various studies of time-restricted eating show participants with obesity losing an average of 3 percent of their body weight, regardless of the time of the eating window. 

Studies showed alternate day fasting resulted in weight loss of 3 percent to 8 percent of body weight over three to eight weeks, with results peaking at 12 weeks. Individuals on alternate day fasting typically do not overeat or binge on feast days, which results in mild to moderate weight loss, according to the review. 

Studies for the 5:2 diet showed similar results to alternate day fasting, which surprised the study's reviewers. The subjects who participate in the 5:2 diet fast much less frequently than alternate-day fasting participants do, but the weight loss results are similar. 

Weight loss with alternate day and 5:2 fasting are comparable to more traditional daily calorie-restrictive diets. And, both fasting diets showed individuals were able to maintain an average of 7 percent weight loss for a year. 

"You're fooling your body into eating a little bit less and that's why people are losing weight," Varady said. 

Varady added the review set out to debunk some myths regarding intermittent fasting. Intermittent fasting does not negatively affect metabolism, nor does it cause disordered eating, according to the studies reviewed. 

"Fasting people are worried about feeling lethargic and not being able to concentrate. Even though you are not eating, it won't affect your energy," Varady said. "A lot of people experience a boost of energy on fasting days. Don't worry, you won't feel crappy. You may even feel better." 

The study review includes a summary of practical considerations for those who may want to try intermittent fasting. Among the considerations are: 

• Adjustment time—Side effects such as headaches, dizziness and constipation subside after one to two weeks of fasting. Increased water intake can help alleviate headaches caused by dehydration during this time. 
• Exercise—Moderate to high-intensity endurance or resistance training during food abstention can be done, and some study participants reported having more energy on fast days. However, studies recommend those following alternate day fasting eat their fasting day meal after exercise. 
• Diet during fasting—There are no specific recommendations for food consumption during intermittent fasting, but eating fruits, vegetables and whole grains can help boost fiber intake and help relieve constipation that sometimes accompanies fasting. 
• Alcohol and caffeine—For those using an alternate day or 5:2 fasting plan, alcohol is not recommended on fast days as the limited calories should be used on healthy foods that provide nutrition. 

There are several groups who should not intermittent fast, according to the studies. Those individuals include: 

• Those who are pregnant or lactating. 
• Children under 12. 
• Those with a history of disordered eating. 
• Those with a body mass index, or BMI, less than 18.5.
• Shift workers. Studies have shown they may struggle with fasting regimens because of shifting work schedules. 
• Those who need to take medication with food at regimented times. 

"People love intermittent fasting because it's easy. People need to find diets that they can stick to long term. It's definitely effective for weight loss and it's gained popularity because there are no special foods or apps necessary. You can also combine it with other diets, like Keto," Varady said. 

Varady has recently been awarded a National Institutes of Health grant to study time-restricted eating for 12 months to see if it works long term.

Antioxidants to prevent Alzheimer's disease

A balanced intake of antioxidants could prevent the development of Alzheimer's disease.

Institut National de la Recherche Scientifique (France), October 13, 2021

Research conducted by the Ph.D student Mohamed Raâfet Ben Khedher and the postdoctoral researcher Mohamed Haddad of the Institut national de la recherche scientifique (INRS) has shown that an oxidation-antioxidant imbalance in the blood is an early indicator of Alzheimer's disease, rather than a consequence. This breakthrough made by researchers under the supervision of the Professor Charles Ramassamy provides an avenue for preventive intervention: the antioxidants intake. 

The research team showed that oxidative markers, known to be involved in Alzheimer's disease, show an increase up to five years before the onset of the disease. The results of this study, published in the Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring (DADM) journal, suggest that oxidation may be an early marker of this disease that affects more than 500,000 Canadians.

“Given that there is an increase in oxidative stress in people who develop the disease, we may regulate the antioxidant systems. For example, we could modulate the antioxidant systems, such as apolipoproteins J and D, which transport lipids and cholesterol in the blood and play an important role in brain function and Alzheimer's disease. Another avenue would be to increase the intake of antioxidants through nutrition”, says Professor Ramassamy. 

Accessible biomarkers

Unlike the current set of invasive and expensive tests used to diagnose Alzheimer's disease, the oxidative markers discovered by Professor Ramassamy's research team can be detected by a blood test. These markers are found in plasma extracellular vesicles, which are pockets released by all cells in the body, including those in the brain.    

The research team focused specifically on the "sporadic" Alzheimer's disease, the most common form of the disease which results primarily from the presence of the APOE4 susceptibility gene. This same form of the disease had been studied by the team for other early markers.

“By identifying oxidative markers in the blood of individuals at risk five years before the onset of the disease, we could make recommendations to slow the onset of the disease and limit the risks”, scientists noted.

This breakthrough brings new hope to Alzheimer's research. Once the disease is symptomatic, it is difficult, if not impossible, to reverse it.    

Meditation training reduces long-term stress, according to hair analysis

Max Planck Institute for Human Cognitive and Brain Sciences (Germany), October 11, 2021

Mental training that promotes skills such as mindfulness, gratitude or compassion reduces the concentration of the stress hormone cortisol in hair. This is what scientists from the Max Planck Institute for Human Cognitive and Brain Sciences in Leipzig and the Social Neuroscience Research Group of the Max Planck Society in Berlin have found out. The amount of cortisol in hair provides information about how much a person is burdened by persistent stress. Earlier positive training effects had been shown in acutely stressful situations or on individual days—or were based on study participants' self-reports.

According to a study by the Techniker Krankenkasse, 23 percent of people in Germany frequently suffer from stress. This condition not only puts a strain on the well-being of those affected, but it is also linked to a number of physiological diseases, including diabetes, cardiovascular diseases and psychological disorders such as depression, one of the world's leading causes of disease burden (Global Burden of Disease Study, 2017).

Therefore, effective methods are being sought to reduce everyday stress in the long term. One promising option is mindfulness training, in which participants train their cognitive and social skills, including attention, gratitude and compassion, through various meditation and behavioral exercises. Various studies have already shown that even healthy people feel less stressed after a typical eight-week training program. Until now, however, it has been unclear how much the training actually contributes to reducing the constant burden of everyday stress. The problem with many previous studies on chronic stress is that the study participants were usually asked to self-assess their stress levels after the training. However, this self-reporting by means of questionnaires could have distorted the effects and made the results appear more positive than they actually were.

The reason for such a bias: The participants knew they were training their mindfulness, and a reduction in stress levels was a desired effect of this training. This awareness alone has an impact on subsequent information. "If you are asked whether you are stressed after a training session that is declared as stress-reducing, even addressing this question can distort the statements," explains Lara Puhlmann, doctoral student at the Max Planck Institute for Human Cognitive and Brain Sciences and first author of the underlying publication, which has now appeared in the journal Psychosomatic Medicine. Factors such as social desirability and placebo effects played a role here. Unlike pharmacological studies, for example, in which the study participants do not know whether they have actually received the active substance or not, so-called blinded studies are not possible in mental training. "The participants know that they are ingesting the 'antidote,'" says Puhlmann. "In mindfulness research, we are therefore increasingly using more objective, i.e. physiological, methods to measure the stress-reducing effect more precisely."

The concentration of cortisol in hair is considered a suitable measure of exposure to prolonged stress. Cortisol is a hormone that is released when we are confronted with an overwhelming challenge, for example. In that particular situation, it helps put our body on alert and mobilize energy to overcome the challenge. The longer the stress lasts, the longer an increased concentration of cortisol circulates around our body—and the more it accumulates in our hair. On average, hair grows one centimeter per month. To measure the study participants' stress levels during the 9-month training, the researchers, in cooperation with the working group of Clemens Kirschbaum at the University of Dresden, analyzed the amount of cortisol every three months in the first three centimeters of hair, starting at the scalp.

The mental training itself was developed as part of a large-scale longitudinal study on the effects of mental training, the ReSource project, led by Tania Singer, scientific director of the Social Neuroscience Research Group. This 9-month mental training program consisted of three 3-month sessions, each designed to train a specific skill area using Western and Far Eastern mental exercises. The focus was either on the factors of attention and mindfulness, on socio-affective skills such as compassion and gratitude, or on so-called socio-cognitive skills, in particular the ability to take perspective on one's own and others' thoughts. Three groups of about 80 participants each completed the training modules in different order. The training lasted up to nine months, 30 minutes a day, six days a week.

Less stress, less cortisol

And it really showed: After six months of training, the amount of cortisol in the subjects' hair had decreased significantly, on average by 25 percent. In the first three months, slight effects were seen at first, which increased over the following three months. In the last third, the concentration remained at a low level. The researchers therefore assume that only sufficiently long training leads to the desired stress-reducing effects. The effect did not seem to depend on the content of the training. It is therefore possible that several of the mental approaches studied are similarly effective in improving the way people deal with chronic everyday stress.

In an earlier study from the ReSource project with the same sample, the researchers had investigated the effects of training on dealing with acute stressful situations. In this study, the participants were placed in a stressful job interview and had to solve difficult maths problems under observation. The results showed that people who had undergone socio-cognitive or socio-affective training released up to 51 percent less cortisol under stress than those who had not been trained. In this case, they did not measure the amount of cortisol in the subjects' hair, but instead acute cortisolsurges in their saliva. Overall, the researchers conclude that training can improve the handling of acute particularly stressful social situations as well as chronic everyday stress. "We assume that different training aspects are particularly helpful for these different forms of stress," says Veronika Engert, head of the research group "Social Stress and Family Health" at the Max Planck Institute for Human Cognitive and Brain Sciences.

"There are many diseases worldwide, including depression, that are directly or indirectly related to long-term stress," explains Puhlmann. "We need to work on counteracting the effects of chronic stress in a preventive way. Our study uses physiological measurements to prove that meditation-based training interventions can alleviate general stress levels even in healthy individuals."

Study: Moderate carbohydrate intake is a cardiovascular benefit for women

Monash University (Australia), October 13, 2021

Women's heart health has been the focus of a recent study by Monash University, with researchers finding that proportional carbohydrate intake and not saturated fat was significantly associated with cardiovascular disease benefit in Australian women.

Cardiovascular disease (CVD) is the leading cause of death in women. Poor diet is recognized as both an independent CVD risk factor and a contributor to other CVD risk factors, such as obesity, diabetes mellitus (DM), hypertension, and dyslipidaemia.

The research found that in middle-aged Australian women, increasing the percentage of carbohydrate intake was significantly associated with reduced odds of CVD, hypertension, diabetes mellitus, and obesity.

Furthermore, a moderate carbohydrate intake between 41.0 percent—44.3 percent of total energy intake was associated with the lowest risk of CVD compared to women who consumed less than 37 percent energy as carbohydrates. No significant relationship was demonstrated between proportional carbohydrate intake and all-cause mortality.

In addition, increasing proportional saturated fat intake was not associated with cardiovascular disease or mortality in women; rather, increasing saturated fat intakecorrelated with lower odds of developing diabetes mellitus, hypertension, and obesity.

The findings are now published in the British Medical Journal.

The results contradict much of the historical epidemiological research that supported a link between saturated fat and CVD. Instead, the results mirror contemporary meta-analysis of prospective cohort studies where saturated fat was found to have no significant relationship with total mortality or CVD.

While the cause of this inconsistency in the literature is unclear, it has been suggested that historical studies neglected to adjust for fiber, which is known to help prevent plaque from forming in the arteries.

"Controversy still exists surrounding the best diet to prevent CVD," said Sarah Zaman, a former Monash University professor who is now an associate professor at the University of Sydney.

"A low-fat diet has historically been the mainstay of primary prevention guidelines, but the major issue within our dietary guidelines is that many dietary trials have predominately involved male participants or lacked sex-specific analyses."

She adds: "Further research is needed to tailor our dietary guidelines according to sex."

The study's first author Sarah Gribbin, a Doctor of Medicine and BMedSc (Hons) student, says: "As an observational study, our findings only show association and not causation. Our research is purely hypothesis-generating. We are hoping that our findings will spark future research into sex-specific dietary research."

The Heart Foundation, which is one of the study's funders, welcomed the focus on women and CVD, which has historically been under-researched.

Heart Foundation manager, food and nutrition, Eithne Cahill, cautioned that "not all carbohydrates are created equal."

"We know that quality carbohydrate foods such as vegetables and whole grains—including whole grain bread, cereals, and pasta—are beneficial for heart health, whereas poor quality carbohydrates such as white bread, biscuits, cakes, and pastries can increase risk," she said.

"Similarly, different fats have different effects on heart health. That is why the Heart Foundation focuses on healthy eating patterns—that is, a combination of foods, chosen regularly over time—rather than a single nutrient or food. Include plenty of vegetables, fruit, and whole grains, and heart-healthy fat choices such as nuts, seeds, avocados, olives and their oils for cooking and a variety of healthy proteins especially seafood, beans and lentils, eggs and dairy."

Anti-cancer effects found in natural compound derived from onions

Kumamoto University (Japan), October 18, 2021

Research from Kumamoto University, Japan has found that a natural compound isolated from onions, onionin A (ONA), has several anti-ovarian cancer properties. This discovery is a result of research on the effects of ONA on a preclinical model of epithelial ovarian cancer (EOC) both in vivo and in vitro. This research comes from the same group that found ONA suppressed pro-tumor activation of host myeloid cells.

According to a 2014 review of cancer medicines from the World Health Organization, EOC is the most common type of ovarian cancer and has a 5-year survival rate of approximately 40%. It has a relatively low lifetime risk that is less than 1%, but that can increase up to 40% if there is a family history of the disease. A majority of patients (80%) experience a relapse after their initial treatment with chemotherapy, therefore a more effective line of treatment is needed.

Kumamoto University researchers found that ONA has several effects on EOC. The group's in vitro experiments showed that EOCs, which usually proliferate in the presence of pro-tumor M2 macrophages, showed inhibited growth after introduction of ONA. This was thought to be due to ONAs influence on STAT3, a transcription factor known to be involved in both M2 polarization and cancer cell proliferation. Furthermore, the team found that ONA inhibited the pro-tumor functions of myeloid derived suppressor cells (MDSC), which are closely associated with the suppression of the anti-tumor immune response of host lymphocytes, by using preclinical sarcoma model. ONA was also found to enhance the effects of anti-cancer drugs by strengthening their anti-proliferation capabilities. Moreover, experiments on an ovarian cancer murine model that investigated the effects of orally administered ONA resulted in longer lifespans and inhibited ovarian cancer tumor development. This was considered to be a result of ONA's suppression of M2 polarized macrophages.

The research shows that ONA reduces the progression of malignant ovarian cancer tumors by interfering with the pro-tumor function of myeloid cells. ONA appears to activate anti-tumor immune responses by nullifying the immunosuppressive function of myeloid cells. ONA has the potential to enhance existing anti-cancer drugs while also having little to no cytotoxic effects on normal cells. Additionally, side effects in animals have not been seen. With a little more testing, an oral ONA supplement should greatly benefit cancer patients.

Risk of chronic diseases caused by exogenous chemical residues

Dalian Institute of Chemical Physics (China), October 13, 2021

Chronic diseases are main killers affecting the health of human. The morbidities of major chronic diseases such as obesity, hypertension, diabetes, hyperuricemia and dyslipidemia are as high as 10% to 30%, showing a gradually upward trend as well.

More and more studies have shown that environmental pollution is a major health risk factor that cannot be ignored. However, the evidence for their relationship is equivocal and the underlying mechanisms is unclear.

Recently, a research group led by Prof. Xu Guowang from the Dalian Institute of Chemical Physics (DICP) of the Chinese Academy of Sciences (CAS) discovered the risk of chronic diseases caused by exogenous chemical residues through metabolome-wide association study.

Their findings were published in Environment International on Oct. 8. Researchers from National Institute for Nutrition and Health of the Chinese Center for Disease Control and Prevention, and Tongji Medical College of Huazhong University of Science and Technology were also involved in this study.

The researchers discovered positive associations of serum perfluoroalkyl substances (PFASs) with hyperuricemia, and revealed the mechanism of the relationship between the exogenous chemical residues in the serum and the risk of chronic diseases at the metabolic level.

The researchers investigated the relationship between 106 exogenous chemical residues and five chronic diseases in 496 serum samples. They revealed the metabolic perturbations related to exogenous chemical residues and chronic diseases by the metabolome-wide association study combined with meeting-in-the-middle approach and mediation analysis, and investigated the further potential underlying mechanism at the metabolic level.

"PFASs were the risk factor for hyperuricemia," said Prof. Xu. Lipid species including glycerophospholipids and glycerides presented the strongest correlation with exposure and disease, which were not only positively related to PFASs exposure but also the risk factor for hyperuricemia. "We also found that key mediation metabolites mediated 25% to 68% of the exposure-disease risk relationship," Prof. Xu added.

This study provides in-depth etiological understanding for the occurrence and development of diseases, which may be helpful for the early detection of the disease and the identification of early warning markers.

The Gary Null Show - 10.19.21

Prof. Eli Schwartz, Director of the Center for Geographic Medicine at Sheba Medical Center in Tel-Hashomer Israel, first introduced the field of travel medicine to Israel .

His practice became the recognized center by the Ministry of Health of Israel for tropical and travel diseases. Dr Schwartz is currently serving as the president of the Israeli Society of Parasitology and Tropical Diseases and past president of the Asia-Pacific Travel Health Society. He is a full Professor (clinical) at the Sacker faculty of Medicine, Tel-Aviv University.

The Gary Null Show - 10.18.21

Lifestyle Modification Improves Physical and Mental Health in Elderly Participants: Observational Study in a Controlled Environment

Gary Null^1*, Ronald Klatz², Robert Goldman², Luanne Pennesi¹, Richard Gale¹, William Faloon³ and Scott Fogle³

¹ Nutrition Institute Of America, New York, United States

² American Academy Of Anti Aging Medicine, N Military Trail, Boca Raton, FL, United States

³ Life Extension Foundation, Ft Lauderdale, FL, United States

^*Corresponding Author(s):

Gary Null
Nutrition Institute Of America, New York, United States
Tel:+1 6469265437,
Email:gary@garynull.com<b

The Gary Null Show - 10.15.21

Dr. Peter McCullough is a distinguished internist, cardiologist, and epidemiologist who has been front and center speaking against the policies and medical flaws in official actions to deal with the covid pandemic. For many he has become regarded as one of the world's experts on Covid-19. Dr. McCullough is also the Chief Medical Advisor for the Truth for Health Foundation, president of the Cardiorenal Society of America Editor in Chief of the peer reviewed journal Reviews in Cardiovascular Medicine and a senior associate editor of the American Journal of Cardiology.  In addition to his internal medicine practice, he also manages common infectious diseases as well as cardiovascular complications associated with viral infection and injuries following Covid-19 vaccination. Since the time the pandemic was declared, Dr. McCullough took a lead in the medical response. He published the first synthesis of sequenced multi-drug treatment for ambulatory patients infected with the SARS-2 virus in the American Journal of Medicine.  He has now published 46 peer-reviewed papers on the infection, reviewed thousands of reports, and has published an additional 700 papers and studies. You can keep up with Peter's reports and analyses on the website AmericaOutLoud.com

The Gary Null Show - 10.14.21

The Gary Null Show - 10.13.21

The Government Assault Against Ivermectin and other Safe SARS-2 Treatments 

Richard Gale and Gary Null PhD

Progressive Radio Network, September 1, 2021

Had the FDA and Anthony Fauci’s National Institute for Allergies and Infectious Disease (NIAID) started approving existing clinically-proven and inexpensive drugs for treating malaria, parasites and other pathogens at the start of the pandemic, millions of people would have been saved from experiencing serious infections or dying from the SARS-CoV-2 virus. Why federal health officials never followed this strategy is a question the mainstream media refuses to ask. 

Another question that the medical establishment, let alone our compliant media, is why have they failed to ask whether there are reliable studies in the peer-reviewed literature and testimonies from thousands of day-to-day clinical physicians worldwide who treat Covid-19 patients with these drugs, in particular hydroxychloroquine (HCQ) and Ivermectin. We may also point out the many different natural remedies, such as nigella sativa, curcumin, vitamin D, melatonin, etc, which have been shown to be effective against SARS-2 infections. In most nations, there has been enormous success in treating Covid patients at the early and moderate stages of infection. However, in the US, Anthony Fauci, Bill Gates, the FDA and our federal medical officials have categorically denied their use.  In fact during the past couple weeks, there has been an aggressive and concerted effort to erect obstacles to prevent the employment of these more effective drugs. More recently a widespread campaign is underway to denigrate them altogether.

For example, the TOGETHER trial is now touted by the mainstream media as a flagship study showing that ivermectin is ineffective and even dangerous to prescribe. The study was conducted by professor Edward Mills at McMaster University in Ontario. If we are to believe the New York Times, the trial, which enrolled 1,300 patients, was discontinued because Mills claimed the drug was no better than a placebo. However, there is strong reason to believe this entire trial was nothing less than a staged theatrical performance. When asked, Mills denied having any conflict of interests.  However, Mills happens to be employed as a clinical trial advisor for the Bill and Melinda Gates Foundation.  The Gates Foundation was also the trial’s principal funder.  It may be noted that various organizations and agencies in other nations, such as the Health Products Regulatory Authority in South Africa, which have banned ivermectin, are often funded by Gates. It is naïve to believe that Gates has any philanthropic intentions whatsoever to see a highly effective treatment for SARS-2 infections reach worldwide approval. These drugs are in direct competition to his enormous investments and unwavering commitment to the Covid-19 vaccines.

In the meantime, Americans only have monoclonal antibody therapy and the controversial and ineffective drug Remdesivir at their disposal. Remdesivir’s average effectiveness for late stage treatment is only 22 percent.  A Chinese study published in The Lancet found no statistically significant benefit in the drug and 12 percent of participants taking the drug had to discontinue treatment due to serious adverse effects, especially liver and kidney damage. 

When questions are posited as a general argument for advocating expedient measures to protect public health during this pandemic, would it not have been wise to have prioritized for emergency use HCQ, Ivermectin, and other remedies with a record of curtailing Covid, such as the antibiotic azithromycin, zinc, selenium, Vitamins C and D, and melatonin as a first line of defense?  There was absolutely no need to have waited for experimental vaccines or experimental drugs such as Remdesivir before the pandemic became uncontrollable.  But this is what Fauci and Trump, and now Biden, permitted to happen.

If this strategy of medical intervention had been followed, would it have been successful?  The answer is likely an unequivocal “yes”.  Both HCQ and, even better, Ivermectin have been prophylactically prescribed by physicians working on pandemic’s front lines with enormous success.  Yet those American physicians struggling to get this urgent message out to federal health officials are being marginalized and ridiculed en masse. Only in the US, the UK, France, South Africa and several other developed nations has there been a stubborn hubris to deny their effectiveness. The World Health Organization recommends Ivermectin for Covid-19 so why not the US and these other nations? Under oath, multiple physicians and professors at American medical schools have testified before Congress to present the scientific evidence supporting HCQ and Ivermectin.  These are otherwise medical professionals at the very heart of treating Covid-19 patients. 

Today, American journalism is in shambles. In fact, it is a disgrace.  The American public is losing trust in the media. Whether it is CNN, the New York Times, the Washington Post, the liberal tabloid Daily Beast, NPR or PBS, each has unlimited resources to properly investigate the federal and institutional machinery behind the government health policies being thrust upon us.  Yet no mainstream journalist has found the moral compass to bring this truth to the public. 

In the meantime, we are allowing millions to die, and countless others to be seriously affected from a severe infection because of professional medical neglect and a healthcare system favoring the pharmaceutical industry’s frantic rush to develop expensive novel drugs and experimental vaccines. The incentive by the drug makers is to take every advantage available within the FDA’s emergency use loopholes to get their products approved as quickly as possible.  The primary advantage is that these novel drugs and vaccines can then leap over regulatory hurdles, which otherwise would require them to conduct lengthy and thorough clinical trials to prove their efficacy and safety. The consequence is that none of the new pharmaceutical Covid-19 interventions have been adequately reviewed.

On the other hand, HCQ and Ivermectin have an established legacy of prior research and have been on the market for decades. Worldwide, it is not unreasonable to claim that billions of people have been treated with these drugs.  

Below is a breakdown of the studies conducted so far for HCQ, Ivermectin and Vitamin D specifically for combatting the SARS-CoV-2 virus

Hydroxychloroquine

344 studies, 250 peer-reviewed have been conducted specifically for Covid-19

281 have been clinical trials that involved 4,583 scientists and over 407,627 patients

64% improvement in 31 early treatment trials

75% improvement in 13 early stage infection treatment mortality results

21% improvement in 190 late stage infection treatment trials (patients in serious condition)

23% improvement in 44 randomized controlled trials

Full list of HCQ studies and details:  https://c19hcq.com

Ivermectin 

131 studies, 52 peer-reviewed have been conducted specifically for Covid-19

63 have been clinical trials that involved 613 scientists and over 26,398 patients

58% improvement in 31 randomized controlled trials 

86% improvement in 14 prophylaxis trials

72% improvement in 27 early stage infection treatment trials

40% improvement in 22 late stage infection treatment trials

58% improvement in 25 mortality results

Full list of Ivermectin studies and details:  https://c19ivermectin.com

Other inexpensive repurposed drugs for treating SARS-2

Fluvoxamine

88% improvement in early treatment

29% improvement in late stage treatment

63% improvement in all 7 peer-reviewed studies

Vitamin D

101 studies conducted by over 875 scientists

63 sufficiency studies with 34,863 patients

33 treatment trials with 46,860 patients

42% improvement in 33 treatment trials

56% improvement in 68 sufficiency studies

55% improvement in 19 treatment mortality results

Full list of Vitamin D studies and details:  https://c19vitamind.com

In contrast there have been 21 studies enrolling 35,744 patients in Remdesivir trials showing only a 22% improvement in all studies combined. This rate is below that of simply taking probiotics (5 studies at 24% improvement), melatonin (7 studies at 62% improvement), curcumin (4 studies at 71% improvement), nigella sativa (3 studies at 84% improvement), quercetin (4 studies at 76% improvement), and aspirin (7 studies at 37% improvement).  Despite the small number of trials and low numbers of enrolled participants, early results indicate that greater attention and funding needs to be allocated for more rigorous research if there is to be any success in curbing SARS-2 infections’ severity.

Please share this information. The inept policies and measures being taken by our federal health officials and by both the former Trump and present Biden administrations are unparalleled in American healthcare history. And never before has the media been so willing to self-censor and been so grossly irresponsible to hide the published science and the truth. 

The Gary Null Show - 10.12.21

The Gary Null Show - 10.11.21

Can low temperature-aged garlic enhance exercise performance?

Korea Univesity & National Institute of Agricultural Sciences (South Korea), October 8, 2021

Scientists from South Korea’s National Institute of Agricultural Sciences and Korea University looked at aged garlic to see whether it could help reduce fatigue. To do this, they conducted a study on mice fed with a special low-temperature-aged garlic (LTAG).

Their findings were published in the Journal of Medicinal Food.

Testing the fatigue-fighting effects of low temperature-aged garlic

The researchers chose to use LTAG because it lacked the pungent odor and spicy flavor of regular garlic, making it easier to use for animal testing.

To create the LTAG, the researchers stored garlic in a sealed container, aging at 60 C for 60 days. The resulting LTAG was then peeled and pulverized, before being added to 200 milliliters of 70 percent ethanol (EtOH), which was then subjected to ultrasonic extraction three times. This 70 percent EtOH and LTAG extract was then concentrated under a vacuum at 45 C and then lyophilized to create a dry LTAG residue.

After the creation of the LTAG, the researchers then separated mice into six groups. The first group was given a low dose of LTAG extract; the second was fed a high dose of LTAG extract; the third was given a low dose of garlic extract; and the fourth was given a high dose of garlic extract. The fifth and sixth groups consisted of normal mice that were given phosphate-buffered saline (PBS) instead of garlic. One of these control groups was made to exercise while the other group was not.

The mice in the five groups were forced to run on a treadmill for four weeks. With each passing week, the amount of exercise the mice would have to do on the treadmills would increase. This was done by increasing both the speed that the mice had to run, and the amount of time they had to spend running. (Related: How to alleviate fatigue with herbal medicine.)

After 28 days of treatment, five mice from each group were subjected to a final, exhaustive treadmill test. This test increased the treadmill speed from 15 meters per minute (m/min) to 40 m/min every 3 minutes. During this test, the running time was monitored until each mouse failed to follow the increase in speed on three consecutive occasions and lag occurred. At this point, the mouse’s total running time was recorded.

The effect of the LTAG on the levels of glucose, lactate dehydrogenase (LDH), free fatty acid (FFA) and lactate in the mice’s blood. Following the final exercise, the mice were killed and blood samples were collected from them. In addition, the mice’s gastrocnemius muscles were also isolated and frozen in liquid nitrogen for testing.

LTAG treated mice demonstrated less fatigue

Following the exhaustive running tests, the researchers found that the mice treated with LTAG extract were able to run for much longer than the control mice.

Meanwhile, looking at the blood tests, they noted that the mice treated with LTAG extract exhibited lower levels of glucose, LDH, FFA and lactate. More importantly, the LTAG treated mice had increased amounts of glycogen and creatine kinase (CK) in their muscles.

Glycogen storage is an important source of energy during exercise. It serves a central role in maintaining the body’s glucose homeostasis by supplementing blood glucose. Because of this, glycogen is seen as an accurate marker for fatigue, with increased glycogel levels closely associated with improved endurance and anti-fatigue effects.

CK, on the other hand, is known to be an accurate indicator of muscle damage. During muscle degeneration, muscle cells are dissolved and their contents enter the bloodstream. As a result, when muscle damage occurs, muscle CK comes out into the blood. As such, fatigue tends to lead to lower muscle CK levels and higher blood CK levels.

Higher levels of glycogen and muscle CK in the LTAG treated mice indicated that they experienced less fatigue than the other groups.

Based on these findings, the researchers believe that LTAG has potential for use as an anti-fatigue agent.

Mindfulness meditation helps preterm-born adolescents

University of Geneva (Switzerland), October 7, 2021

Adolescents born prematurely present a high risk of developing executive, behavioral and socio-emotional difficulties. Now, researchers from Geneva University Hospitals (HUG) and the University of Geneva (UNIGE) have revealed that practicing mindfulness may help improve these various skills. The study, published in the journal Scientific Reports, suggests using mindfulness as a means of clinical intervention with adolescents, whether prematurely born or not.

Several studies have already shown that very preterm (VPT) children and adolescents are at higher risk of exhibiting cognitive and socio-emotional problems that may persist into adulthood. To help them overcome the difficulties they face, researchers from the HUG and UNIGE have set up an intervention based on mindfulness, a technique known to have beneficial effects in these areas. Mindfulness consists in training the mind to focus on the present moment, concentrating on physical sensations, on breathing, on the weight of one's body, and even on one's feelings and thoughts, completely judgment-free. The mindfulness-based interventions generally take place in a group with an instructor along with invitations to practice individually at home.

To accurately assess the effects of mindfulness, a randomized controlled trial was performed with young adolescents aged 10 to 14, born before 32 weeks gestational weeks. Scientists quickly found that mindfulness improves the regulation of cognitive, social and emotional functions, in other worlds, our brain's ability to interact with our environment. Indeed, it increases the ability to focus on the present—on thoughts, emotions and physical sensations, with curiosity and non-judgment. Thanks to this practice, adolescents improve their executive functions, i.e. the mental processes that enable us to control our behavior to successfully achieve a goal. As a result, young people find it easier to focus, manage and regulate their behavior and emotions in everyday life.

For eight weeks, the young teens spent an hour and a half each week with two mindfulness instructors. They were further encouraged to practice mindfulness daily at home.

Parents were also involved in this study. They were asked to observe their child's executive functions, for example the ability to regulate their emotions and attentional control, their relationships with others and their behavior. The adolescents also underwent a series of computerized tasks to assess their reactions to events. A comparison of their test results with a control group that did not practice mindfulness shows a positive impact of the intervention on the adolescents' everyday life and on their ability to react to new events.

"Each teenager is unique, with their own strenghts and difficulties. Through their involvement in this study, our volunteers have contributed to show that mindfulness can help many young people to feel better, to refocus and to face the world, whether they were born preterm born or not," agree Dr. Russia Hà-Vinh Leuchter, a consultant in the Division of Development and Growth, Department of Paediatrics, Gynaecology and Obstetrics at Geneva University Hospitals, and Dr. Vanessa Siffredi, a researcher at the Child Development Laboratory at the Department of Paediatrics, Gynaecology and Obstetrics at the UNIGE Faculty of Medicine, two of the authors of this work. "However, while the practice of meditation can be a useful resource, it is important to be accompanied by well-trained instructors", they specify.

The adolescents who took part in the program are now between 14 and 18 years. Scientists are currently evaluating the long-term effects of mindfulness-based intervention on their daily attention and stress. Furthermore, to validate their clinical data with neurobiological measurements, researchers are currently studying the effects of mindfulness on the brain using magnetic resonance imaging (MRI).

Iron deficiency in middle age is linked with higher risk of developing heart disease

University Heart and Vasculature Centre Hamburg (Germany) 6 October 2021

Approximately 10% of new coronary heart disease cases occurring within a decade of middle age could be avoided by preventing iron deficiency, suggests a study published today in ESC Heart Failure, a journal of the European Society of Cardiology (ESC).1

“This was an observational study and we cannot conclude that iron deficiency causes heart disease,” said study author Dr. Benedikt Schrage of the University Heart and Vasculature Centre Hamburg, Germany. “However, evidence is growing that there is a link and these findings provide the basis for further research to confirm the results.”

Previous studies have shown that in patients with cardiovascular diseases such as heart failure, iron deficiency was linked to worse outcomes including hospitalisations and death. Treatment with intravenous iron improved symptoms, functional capacity, and quality of life in patients with heart failure and iron deficiency enrolled in the FAIR-HF trial.2 Based on these results, the FAIR-HF 2 trial is investigating the impact of intravenous iron supplementation on the risk of death in patients with heart failure.

The current study aimed to examine whether the association between iron deficiency and outcomes was also observed in the general population.

The study included 12,164 individuals from three European population-based cohorts. The median age was 59 years and 55% were women. During the baseline study visit, cardiovascular risk factors and comorbidities such as smoking, obesity, diabetes and cholesterol were assessed via a thorough clinical assessment including blood samples.

Participants were classified as iron deficient or not according to two definitions: 1) absolute iron deficiency, which only includes stored iron (ferritin); and 2) functional iron deficiency, which includes iron in storage (ferritin) and iron in circulation for use by the body (transferrin).

Dr. Schrage explained: “Absolute iron deficiency is the traditional way of assessing iron status but it misses circulating iron. The functional definition is more accurate as it includes both measures and picks up those with sufficient stores but not enough in circulation for the body to work properly.”

Participants were followed up for incident coronary heart disease and stroke, death due to cardiovascular disease, and all-cause death. The researchers analysed the association between iron deficiency and incident coronary heart disease, stroke, cardiovascular mortality, and all-cause mortality after adjustments for age, sex, smoking, cholesterol, blood pressure, diabetes, body mass index, and inflammation. Participants with a history of coronary heart disease or stroke at baseline were excluded from the incident disease analyses.

At baseline, 60% of participants had absolute iron deficiency and 64% had functional iron deficiency. During a median follow-up of 13.3 years there were 2,212 (18.2%) deaths. Of these, a total of 573 individuals (4.7%) died from a cardiovascular cause. Incidence coronary heart disease and stroke were diagnosed in 1,033 (8.5%) and 766 (6.3%) participants, respectively.

Functional iron deficiency was associated with a 24% higher risk of coronary heart disease, 26% raised risk of cardiovascular mortality, and 12% increased risk of all-cause mortality compared with no functional iron deficiency. Absolute iron deficiency was associated with a 20% raised risk of coronary heart disease compared with no absolute iron deficiency, but was not linked with mortality. There were no associations between iron status and incident stroke.

The researchers calculated the population attributable fraction, which estimates the proportion of events in 10 years that would have been avoided if all individuals had the risk of those without iron deficiency at baseline. The models were adjusted for age, sex, smoking, cholesterol, blood pressure, diabetes, body mass index, and inflammation. Within a 10-year period, 5.4% of all deaths, 11.7% of cardiovascular deaths, and 10.7% of new coronary heart disease diagnoses were attributable to functional iron deficiency.

“This analysis suggests that if iron deficiency had been absent at baseline, about 5% of deaths, 12% of cardiovascular deaths, and 11% of new coronary heart disease diagnoses would not have occurred in the following decade,” said Dr. Schrage.

“The study showed that iron deficiency was highly prevalent in this middle-aged population, with nearly two-thirds having functional iron deficiency,” said Dr. Schrage. “These individuals were more likely to develop heart disease and were also more likely to die during the next 13 years.”

Dr. Schrage noted that future studies should examine these associations in younger and non-European cohorts. He said: “If the relationships are confirmed, the next step would be a randomised trial investigating the effect of treating iron deficiency in the general population.”

Consumption of a bioactive compound from Neem plant could significantly suppress development of prostate cancer

National University of Singapore, September 29, 2021

Oral administration of nimbolide, over 12 weeks shows reduction of prostate tumor size by up to 70 per cent and decrease in tumor metastasis by up to 50 per cent

A team of international researchers led by Associate Professor Gautam Sethi from the Department of Pharmacology at the Yong Loo Lin School of Medicine at the National University of Singapore (NUS) has found that nimbolide, a bioactive terpenoid compound derived from Azadirachta indica or more commonly known as the neem plant, could reduce the size of prostate tumor by up to 70 per cent and suppress its spread or metastasis by half.

Prostate cancer is one of the most commonly diagnosed cancers worldwide. However, currently available therapies for metastatic prostate cancer are only marginally effective. Hence, there is a need for more novel treatment alternatives and options.

"Although the diverse anti-cancer effects of nimbolide have been reported in different cancer types, its potential effects on prostate cancer initiation and progression have not been demonstrated in scientific studies. In this research, we have demonstrated that nimbolide can inhibit tumor cell viability -- a cellular process that directly affects the ability of a cell to proliferate, grow, divide, or repair damaged cell components -- and induce programmed cell death in prostate cancer cells," said Assoc Prof Sethi.

Nimbolide: promising effects on prostate cancer

Cell invasion and migration are key steps during tumor metastasis. The NUS-led study revealed that nimbolide can significantly suppress cell invasion and migration of prostate cancer cells, suggesting its ability to reduce tumor metastasis.

The researchers observed that upon the 12 weeks of administering nimbolide, the size of prostate cancer tumor was reduced by as much as 70 per cent and its metastasis decreased by about 50 per cent, without exhibiting any significant adverse effects.

"This is possible because a direct target of nimbolide in prostate cancer is glutathione reductase, an enzyme which is responsible for maintaining the antioxidant system that regulates the STAT3 gene in the body. The activation of the STAT3 gene has been reported to contribute to prostate tumor growth and metastasis," explained Assoc Prof Sethi. "We have found that nimbolide can substantially inhibit STAT3 activation and thereby abrogating the growth and metastasis of prostate tumor," he added.

The findings of the study were published in the April 2016 issue of the scientific journal Antioxidants & Redox Signaling. This work was carried out in collaboration with Professor Goh Boon Cher of Cancer Science Institute of Singapore at NUS, Professor Hui Kam Man of National Cancer Centre Singapore and Professor Ahn Kwang Seok of Kyung Hee University.

The neem plant belongs to the mahogany tree family that is originally native to India and the Indian sub-continent. It has been part of traditional Asian medicine for centuries and is typically used in Indian Ayurvedic medicine. Today, neem leaves and bark have been incorporated into many personal care products such as soaps, toothpaste, skincare and even dietary supplements.

Review looks at the efficacy of acupuncture in treating insulin resistance

Guangzhou University of Chinese Medicine (China), October 8, 2021

In their report, researcherss from Guangzhou University of Chinese Medicine in China explored the role of acupuncture in treating insulin resistance. The study was published in the journal Complementary Therapies in Clinical Practice.

• Earlier studies have reported the effectiveness of acupuncture in treating insulin resistance and related conditions.
• The review looked at acupuncture and its effects on clinical outcomes.
• The researchers searched the following databases for randomized controlled trials involving insulin resistance patients treated with acupuncture:
  • Cochrane Central Register of Controlled Trials
  • Embase
  • Medline (via OVID)
  • China National Knowledge Infrastructure (CNKI)
  • Wan Fang and China Science and Technology Journal Database (VIP)
• The studies show that homeostasis model assessment of insulin resistance significantly decreased with acupuncture treatment.
• Other significant decreases include fasting blood glucose, postprandial blood glucose and fasting insulin.
• Acupuncture increased insulin sensitivity with very few adverse effects.

In sum, acupuncture is a safe and effective alternative treatment for insulin resistance.

Blueberries may improve attention in children following double-blind trial

University of Reading (UK), October 10, 2021 

Primary school children could show better attention by consuming flavonoid-rich blueberries, following a study conducted by the University of Reading.

In a paper published in Food & Function, a group of 7-10 year olds who consumed a drink containing wild blueberries or a matched placebo and were tested on their speed and accuracy in completing an executive task function on a computer.

The double blind trial found that the children who consumed the flavonoid-rich blueberry drink had 9% quicker reaction times on the test without any sacrifice of accuracy. In particular, the effect was more noticeable as the tests got harder.

Professor Claire Williams, a neuroscience professor at the University of Reading said:

"This is the first time that we have seen the positive impact that flavonoids can have on the executive function of children. We designed this double blind trial especially to test how flavonoids would impact on attention in young people as it's an area of cognitive performance that hasn't been measured before.

"We used wild blueberries as they are rich in flavonoids, which are compounds found naturally in foods such as fruits and their juices, vegetables and tea. They have been associated with a range of health benefits including antioxidant and anti-inflammatory effects, and our latest findings continue to show that there is a beneficial cognitive effect of consuming fruit and vegetables, tea, coffee and even dark chocolate which all contain flavonoids."

The children were then asked to pay attention to an array of arrows shown on a PC screen and press a key corresponding to the direction that the central arrow was facing. The task was repeated over a number of trials, where cognitive demand was manipulated by varying how quickly the arrows appeared, whether there were additional arrows appearing either side of the central arrow, and whether the flanking arrows were pointing in the same/different direction as the central arrow.

Previous Reading research has shown that consuming wild blueberries can improve mood in children and young people, simple memory recall in primary school children, and that other flavonoid rich drinks such as orange juice, can also improve memory and concentration.

The Wild Blueberry Association of North America provided a freeze-dried powder made from wild blueberries which was used in the study but did not provide any additional financial support and did not play a role in the design of the study.

Wild blueberries are grown and harvested in North America, and are smaller than regular blueberries, and are higher in flavonoids compared to regular varieties.

The double-blind trial used a flavonoid-rich wild blueberry drink, with a matched placebo contained 8.9g of fructose, 7.99g of glucose and 4 mg of vitamin C matching the levels of nutrients found in the blueberry drink.

The amount of fructose is akin to levels found in a standard pear.

This was an executive function task- requiring participants to pay attention to stimuli appearing on screen and responding correctly. The task was a simple one- responding to the direction of an arrow in the middle of a screen (by pressing left/right arrow key) but we then varied how quickly the stimuli appeared, whether there was additional arrows appearing either side of the stimuli and whether those flanking arrows were pointing in the same/different direction as they direction you had to respond.

There are 6 main classes of flavonoids:

• Anthocyanins – found in berry fruits such as the blueberries used in this study and also in red wine.
• Flavonols - found in onions, leeks, and broccoli
• Flavones - found in parsley and celery,
• Isoflavones - found in soy and soy products,
• Flavanones - found in citrus fruit and tomatoes
• Flavanols—found in green tea, red wine, and chocolate

Nocebo effect: Does a drug's high price tag cause its own side effects?

University Medical Center Hamburg (Germany), October 5, 2021 

Pricey drugs may make people more vulnerable to perceiving side effects, a new study suggests—and the phenomenon is not just "in their heads."

The study delved into the so-called "nocebo effect." It's the negative version of the well-known placebo effect, where people feel better after receiving a therapy because they expected good things.

With the nocebo effect, patients' worries over treatment side effects make them feel sick.

In this study, researchers found that people were more likely to report painful side effects from a fake drug when told it was expensive.

But it wasn't just something people were "making up." Using brain imaging, the researchers traced the phenomenon to specific activity patterns in the brain and spine.

"These findings are a strong argument against the perception of placebo and nocebo effects as being only 'fake' effects—created purely by imagination or delusions of the patient," said lead researcher Alexandra Tinnermann. She is with the University Medical Center Hamburg-Eppendorf, in Germany.

Dr. Luana Colloca, a researcher at the University of Maryland in Baltimore, agreed.

"This is not merely a reflection of people's biases," said Colloca, who wrote an editorial published with the study.

"Expectations do modulate symptoms and patients' responses to treatment," she said.

For the study, Tinnermann's team recruited 49 healthy volunteers and randomly assigned them to test one of two itch-relieving "medical creams."

In reality, both creams were identical and contained no active ingredients. However, people in both groups were told that the products could have the side effect of making the skin more sensitive to pain.

There was only one apparent difference between the two phony creams: One came in fancy packing with a high price tag; the other was cheap.

After participants applied the creams to their forearms, the researchers had them undergo a standard test that measured their tolerance for heat-induced pain.

It turned out that people who'd used the expensive cream were more sensitive to pain during the tests. On average, their pain rating hovered around a 15—within the "mild" pain range—whereas people using the cheap cream barely registered any discomfort.

It's likely, Tinnermann said, that people expect a pricey medication to be potent—which could also make them expect more side effects.

Colloca agreed. We are all "vulnerable" to such outside influences, she said, be it a drug's price or how it's given (by IV versus mouth, for instance).

However, we are not just imagining those placebo or nocebo effects, both researchers noted.

Using functional MRI brain scans, Tinnermann's team found specific patterns of nervous system activity in people who had a nocebo response to the pricey cream.

That included a change in "communication" between certain brain structures and the spinal cord, Tinnermann said.

According to Colloca, research like this can have practical uses. Doctors could, for instance, inform patients that drug prices or other factors can sway their expectations about a treatment's benefits and risks—and that, in turn, can influence whether they feel better or develop side effects.

There is, however, no research into whether that kind of knowledge helps prevent patients from the nocebo effect, Tinnermann said.

But, she added, health professionals can be aware that patients' expectations "play a huge role in medicine"—and be mindful of how they talk about a medication and its possible side effects.

It's an important matter, Colloca said, because the nocebo effect can cause people to stop taking needed medications.

Colloca pointed to the example of cholesterol-lowering statins.

The potential for those medications to cause muscle pain has been widely reported. And one recent study found evidence that this knowledge can make statin users more likely to report muscle pain side effects.

Other research, Colloca said, has shown that when people stop taking their statins, their risk of heart attack and stroke rises.

The Gary Null Show - 10.08.21

Raspberries, ellagic acid reveal benefits in two studies

Oregon State University, October 1, 2021. 

Articles that appeared recently in the Journal of Berry Research report that raspberries and compounds present in the fruit could help support healthy body mass and motor function, including balance, coordination and strength.

In one study, Neil Shay and colleagues at Oregon State University fed mice a high fat, high sugar diet plus one of the following: raspberry juice concentrate, raspberry puree concentrate, raspberry fruit powder, raspberry seed extract, ellagic acid (a polyphenol that occurs in a relatively high amount in raspberries), raspberry ketone, or a combination of raspberry ketone and ellagic acid. Additional groups of animals received a high fat, high sugar diet alone or a low fat diet.

While mice that received the high fat and sugar diet alone experienced a significant increase in body mass, the addition of raspberry juice concentrate, raspberry puree concentrate or ellagic acid plus raspberry ketone helped prevent this effect. Of note, mice that received raspberry juice concentrate experienced gains similar to those of animals given a low fat diet. "We hope that the findings from this study can help guide the design of future clinical trials," Dr Shay stated.

In another study, Barbara Shukitt-Hale, PhD, and her associates at Tufts University's Human Nutrition Research Center on Aging gave 19 month old rats a control diet or a diet enhanced with raspberry extract for 11 weeks. Psychomotor behavior was assessed during week 7 and cognitive testing was conducted during weeks 9-10.

Animals that received raspberry performed better on psychomotor coordination and balance, and had better muscle tone, strength and stamina than those that received a control diet. "These results may have important implications for healthy aging," stated Dr Shukitt-Hale. "While further research in humans is necessary, animal model studies are helpful in identifying deficits associated with normal aging."

Massage doesn't just make muscles feel better, it makes them heal faster and stronger

Harvard University, October 6, 2021

Massage has been used to treat sore, injured muscles for more than 3,000 years, and today many athletes swear by massage guns to rehabilitate their bodies. But other than making people feel good, do these "mechanotherapies" actually improve healing after severe injury? According to a new study from researchers at Harvard's Wyss Institute for Biologically Inspired Engineering and John A. Paulson School of Engineering and Applied Sciences (SEAS), the answer is "yes."

Using a custom-designed robotic system to deliver consistent and tunable compressive forces to mice's leg muscles, the team found that this mechanical loading (ML) rapidly clears immune cells called neutrophils out of severely injured muscle tissue. This process also removed inflammatory cytokinesreleased by neutrophils from the muscles, enhancing the process of muscle fiber regeneration. The research is published in Science Translational Medicine.

"Lots of people have been trying to study the beneficial effects of massage and other mechanotherapies on the body, but up to this point it hadn't been done in a systematic, reproducible way. Our work shows a very clear connection between mechanical stimulation and immune function. This has promise for regenerating a wide variety of tissues including bone, tendon, hair, and skin, and can also be used in patients with diseases that prevent the use of drug-based interventions," said first author Bo Ri Seo, Ph.D., who is a Postdoctoral Fellow in the lab of Core Faculty member Dave Mooney, Ph.D. at the Wyss Institute and SEAS.

Seo and her coauthors started exploring the effects of mechanotherapy on injured tissues in mice several years ago, and found that it doubled the rate of muscle regeneration and reduced tissue scarring over the course of two weeks. Excited by the idea that mechanical stimulation alone can foster regeneration and enhance muscle function, the team decided to probe more deeply into exactly how that process worked in the body, and to figure out what parameters would maximize healing.

They teamed up with soft robotics experts in the Harvard Biodesign Lab, led by Wyss Associate Faculty member Conor Walsh, Ph.D., to create a small device that used sensors and actuators to monitor and control the force applied to the limb of a mouse. " The device we created allows us to precisely control parameters like the amount and frequency of force applied, enabling a much more systematic approach to understanding tissue healing than would be possible with a manual approach," said co-second author Christopher Payne, Ph.D., a former Postdoctoral Fellow at the Wyss Institute and the Harvard Biodesign Lab who is now a Robotics Engineer at Viam, Inc. 

Once the device was ready, the team experimented with applying force to mice's leg muscles via a soft silicone tip and used ultrasound to get a look at what happened to the tissue in response. They observed that the muscles experienced a strain of between 10-40%, confirming that the tissues were experiencing mechanical force. They also used those ultrasound imaging data to develop and validate a computational model that could predict the amount of tissue strain under different loading forces.

They then applied consistent, repeated force to injured muscles for 14 days. While both treated and untreated muscles displayed a reduction in the amount of damaged muscle fibers, the reduction was more pronounced and the cross-sectional area of the fibers was larger in the treated muscle, indicating that treatment had led to greater repair and strength recovery. The greater the force applied during treatment, the stronger the injured muscles became, confirming that mechanotherapy improves muscle recovery after injury. But how?

Evicting neutrophils to enhance regeneration

To answer that question, the scientists performed a detailed biological assessment, analyzing a wide range of inflammation-related factors called cytokines and chemokines in untreated vs. treated muscles. A subset of cytokines was dramatically lower in treated muscles after three days of mechanotherapy, and these cytokines are associated with the movement of immune cells called neutrophils, which play many roles in the inflammation process. Treated muscles also had fewer neutrophils in their tissue than untreated muscles, suggesting that the reduction in cytokines that attract them had caused the decrease in neutrophil infiltration.

The team had a hunch that the force applied to the muscle by the mechanotherapy effectively squeezed the neutrophils and cytokines out of the injured tissue. They confirmed this theory by injecting fluorescent molecules into the muscles and observing that the movement of the molecules was more significant with force application, supporting the idea that it helped to flush out the muscle tissue.

To pick apart what effect the neutrophils and their associated cytokines have on regenerating muscle fibers, the scientists performed in vitro studies in which they grew muscle progenitor cells (MPCs) in a medium in which neutrophils had previously been grown. They found that the number of MPCs increased, but the rate at which they differentiated (developed into other cell types) decreased, suggesting that neutrophil-secreted factors stimulate the growth of muscle cells, but the prolonged presence of those factors impairs the production of new muscle fibers.

"Neutrophils are known to kill and clear out pathogens and damaged tissue, but in this study we identified their direct impacts on muscle progenitor cell behaviors," said co-second author Stephanie McNamara, a former Post-Graduate Fellow at the Wyss Institute who is now an M.D.-Ph.D. student at Harvard Medical School (HMS). "While the inflammatory response is important for regeneration in the initial stages of healing, it is equally important that inflammation is quickly resolved to enable the regenerative processes to run its full course."

Seo and her colleagues then turned back to their in vivo model and analyzed the types of muscle fibers in the treated vs. untreated mice 14 days after injury. They found that type IIX fibers were prevalent in healthy muscle and treated muscle, but untreated injured muscle contained smaller numbers of type IIX fibers and increased numbers of type IIA fibers. This difference explained the enlarged fiber size and greater force production of treated muscles, as IIX fibers produce more force than IIA fibers.

Finally, the team homed in on the optimal amount of time for neutrophil presence in injured muscle by depleting neutrophils in the mice on the third day after injury. The treated mice's muscles showed larger fiber size and greater strength recovery than those in untreated mice, confirming that while neutrophils are necessary in the earliest stages of injury recovery, getting them out of the injury site early leads to improved muscle regeneration.

"These findings are remarkable because they indicate that we can influence the function of the body's immune system in a drug-free, non-invasive way," said Walsh, who is also the Paul A. Maeder Professor of Engineering and Applied Science at SEAS and whose group is experienced in developing wearable technology for diagnosing and treating disease. "This provides great motivation for the development of external, mechanical interventions to help accelerate and improve muscle and tissue healing that have the potential to be rapidly translated to the clinic."

The team is continuing to investigate this line of research with multiple projects in the lab. They plan to validate this mechanotherpeutic approach in larger animals, with the goal of being able to test its efficacy on humans. They also hope to test it on different types of injuries, age-related muscle loss, and muscle performance enhancement.

"The fields of mechanotherapy and immunotherapy rarely interact with each other, but this work is a testament to how crucial it is to consider both physical and biological elements when studying and working to improve human health," said Mooney, who is the corresponding author of the paper and the Robert P. Pinkas Family Professor of Bioengineering at SEAS.

"The idea that mechanics influence cell and tissue function was ridiculed until the last few decades, and while scientists have made great strides in establishing acceptance of this fact, we still know very little about how that process actually works at the organ level. This research has revealed a previously unknown type of interplay between mechanobiology and immunology that is critical for muscle tissue healing, in addition to describing a new form of mechanotherapy that potentially could be as potent as chemical or gene therapies, but much simpler and less invasive," said Wyss Founding Director Don Ingber, M.D., Ph.D., who is also the Judah Folkman Professor of Vascular Biology at (HMS) and the Vascular Biology Program at Boston Children's Hospital, as well as Professor of Bioengineering at SEAS.

Vitamin E could help protect older men from pneumonia

University of Helsinki (Finland), October 7 2021. 

An article that appeared in Clinical Interventions in Aging reported a protective role for vitamin E against pneumonia in older men.

For the current investigation, Dr Harri Hemilä of the University of Helsinki, Finland analyzed data from the Alpha-Tocopherol Beta-Carotene (ATBC) Cancer Prevention Study conducted in Finland. The trial included 29,133 men between the ages of 50 to 69 years who smoked at least five cigarettes daily upon enrollment. Participants received alpha tocopherol (vitamin E), beta carotene, both supplements, or a placebo for five to eight years.

The current study was limited to 7,469 ATBC participants who started smoking at age 21 or older. Among this group, supplementation with vitamin E was associated with a 35% lower risk of developing pneumonia in comparison with those who did not receive the vitamin.  Light smokers who engaged in leisure time exercise had a 69% lower risk compared with unsupplemented members of this subgroup. The risk in this subgroup of developing pneumonia by age 74 was 12.9%.

Among the one-third of the current study's population who quit smoking for a median period of two years, there was a 72% lower risk of pneumonia in association with vitamin E supplementation. In this group, exercisers who received vitamin E experienced an 81% lower pneumonia risk.

Dr Hemilä observed that the benefit for vitamin E in this study was strongest for older subjects—a group at higher risk of pneumonia.

"The current analysis of individual-level data suggests that trials on vitamin E and pneumonia on nonsmoking elderly males are warranted," he concluded.

Toxic fatty acids to blame for brain cell death after injury

New York University, October 7, 2021

Cells that normally nourish healthy brain cells called neurons release toxic fatty acids after neurons are damaged, a new study in rodents shows. This phenomenon is likely the driving factor behind most, if not all, diseases that affect brain function, as well as the natural breakdown of brain cells seen in aging, researchers say.

Previous research has pointed to astrocytes—a star-shaped glial cell of the central nervous system—as the culprits behind cell death seen in Parkinson's disease and dementia, among other neurodegenerative diseases. While many experts believed that these cells released a neuron-killing molecule to "clear away" damaged brain cells, the identity of this toxin has until now remained a mystery.

Led by researchers at NYU Grossman School of Medicine, the new investigation provides what they say is the first evidence that tissue damage prompts astrocytes to produce two kinds of fats, long-chain saturated free fatty acids and phosphatidylcholines. These fats then trigger cell death in damaged neurons, the electrically active cells that send messages throughout nerve tissue.

Publishing Oct. 6 in the journal Nature, the study also showed that when researchers blocked fatty acid formation in mice, 75 percent of neurons survived compared with 10 percent when the fatty acids were allowed to form. The researchers' earlier work showed that brain cells continued to function when shielded from astrocyte attacks. 

"Our findings show that the toxic fatty acids produced by astrocytes play a critical role in brain cell death and provide a promising new target for treating, and perhaps even preventing, many neurodegenerative diseases," says study co-senior author Shane Liddelow, Ph.D.

Liddelow, an assistant professor in the Department of Neuroscience and Physiology at NYU Langone Health, adds that targeting these fats instead of the cells that produce them may be a safer approach to treating neurodegenerative diseasesbecause astrocytes feed nerve cells and clear away their waste. Stopping them from working altogether could interfere with healthy brain function.

Although it remains unclear why astrocytes produce these toxins, it is possible they evolved to destroy damaged cells before they can harm their neighbors, says Liddelow. He notes that while healthy cells are not harmed by the toxins, neurons become susceptible to the damaging effects when they are injured, mutated, or infected by prions, the contagious, misfolded proteins that play a major role in mad cow disease and similar illnesses. Perhaps in chronic diseases like dementia, this otherwise helpful process goes off track and becomes a problem, the study authors say.

For the investigation, researchers analyzed the molecules released by astrocytes collected from rodents. They also genetically engineered some groups of mice to prevent the normal production of the toxic fats and looked to see whether neuron death occurred after an acute injury.

"Our results provide what is likely the most detailed molecular map to date of how tissue damage leads to brain cell death, enabling researchers to better understand why neurons die in all kinds of diseases," says Liddelow, also an assistant professor in the Department of Ophthalmology at NYU Langone.

Liddelow cautions that while the findings are promising, the genetic techniques used to block the enzyme that produces toxic fatty acids in mice are not ready for use in humans. As a result, the researchers next plan is to explore safe and effective ways to interfere with the release of the toxins in human patients. Liddelow and his colleagues had previously shown these neurotoxic astrocytes in the brains of patients with Parkinson's, Huntington's disease, and multiple sclerosis, among other diseases.

Clinical trial for nicotinamide riboside: Vitamin safely boosts levels of important cell metabolite linked to multiple health benefits

University of Iowa Health Care, October 3, 2021

In the first controlled clinical trial of nicotinamide riboside (NR), a newly discovered form of Vitamin B3, researchers have shown that the compound is safe for humans and increases levels of a cell metabolite that is critical for cellular energy production and protection against stress and DNA damage.

Studies in mice have shown that boosting the levels of this cell metabolite -- known as NAD+ -- can produce multiple health benefits, including resistance to weight gain, improved control of blood sugar and cholesterol, reduced nerve damage, and longer lifespan. Levels of NAD+ diminish with age, and it has been suggested that loss of this metabolite may play a role in age-related health decline.

These findings in animal studies have spurred people to take commercially available NR supplements designed to boost NAD+. However, these over-the-counter supplements have not undergone clinical trials to see if they work in people.

The new research, reported in the journal Nature Communications, was led by Charles Brenner, PhD, professor and Roy J. Carver Chair of Biochemistry at the University of Iowa Carver College of Medicine in collaboration with colleagues at Queens University Belfast and ChromaDex Corp. (NASDAQ: CDXC), which supplied the NR used in the trial. Brenner is a consultant for ChromaDex. He also is co-founder and Chief Scientific Adviser of ProHealthspan, which sells NR supplements under the trade name Tru NIAGEN®.

The human trial involved six men and six women, all healthy. Each participant received single oral doses of 100 mg, 300 mg, or 1,000 mg of NR in a different sequence with a seven-day gap between doses. After each dose, blood and urine samples were collected and analyzed by Brenner's lab to measure various NAD+ metabolites in a process called metabolomics. The trial showed that the NR vitamin increased NAD+ metabolism by amounts directly related to the dose, and there were no serious side effects with any of the doses.

"This trial shows that oral NR safely boosts human NAD+ metabolism," Brenner says. "We are excited because everything we are learning from animal systems indicates that the effectiveness of NR depends on preserving and/or boosting NAD+ and related compounds in the face of metabolic stresses. Because the levels of supplementation in mice that produce beneficial effects are achievable in people, it appears than health benefits of NR will be translatable to humans safely."

The next step will be to study the effect of longer duration NR supplementation on NAD+ metabolism in healthy adults, but Brenner also has plans to test the effects of NR in people with diseases and health conditions, including elevated cholesterol, obesity and diabetes, and people at risk for chemotherapeutic peripheral neuropathy.

Prior to the formal clinical trial, Brenner conducted a pilot human study -- on himself. In 2004, he had discovered that NR is a natural product found in milk and that there is pathway to convert NR to NAD+ in people. More than a decade of research on NR metabolic pathways and health effects in mice and rats had convinced him that NR supplementation had real promise to improve human health and wellness. After consulting with UI's institutional review board, he conducted an experiment in which he took 1 gram of NR once a day for seven days, and his team analyzed blood and urine samples using mass spectrometry. The experiment showed that Brenner's blood NAD+ increased by about 2.7 times. In addition, though he reported immediate sensitivity to flushing with the related compound niacin, he did not experience any side effects taking NR.

The biggest surprise from his metabolomic analysis was an increase in a metabolite called NAAD, which was multiplied by 45 times, from trace levels to amounts in the micromolar range that were easily detectable.

"While this was unexpected, I thought it might be useful," Brenner says. "NAD+ is an abundant metabolite and it is sometimes hard to see the needle move on levels of abundant metabolites. But when you can look at a low-abundance metabolite that goes from undetectable to easily detectable, there is a great signal to noise ratio, meaning that NAAD levels could be a useful biomarker for tracking increases in NAD+ in human trials."

Brenner notes this was a case of bidirectional translational science; having learned something from the initial human experiment, his team was able to return to laboratory mice to explore the unexpected NAAD finding in more detail.

Brenner's mouse study showed that NAAD is formed from NR and confirmed that NAAD levels are a strong biomarker for increased NAD+ metabolism. The experiments also revealed more detail about NAD+ metabolic pathways.

In particular, the researchers compared the ability of all three NAD+ precursor vitamins -- NR, niacin, and nicotinamide -- to boost NAD+ metabolism and stimulate the activity of certain enzymes, which have been linked to longevity and healthbenefits. The study showed for the first time that oral NR is superior to nicotinamide, which is better than niacin in terms of the total amount of NAD+ produced at an equivalent dose. NR was also the best of the three in stimulating the activity of sirtuin enzymes. However, in this case, NR was the best at stimulating sirtuin-like activities, followed by niacin, followed by nicotinamide.

The information from the mouse study subsequently helped Brenner's team design the formal clinical trial. In addition to showing that NR boosts NAD+ in humans without adverse effects, the trial confirmed that NAAD is a highly sensitive biomarker of NAD+ supplementation in people.

"Now that we have demonstrated safety in this small clinical trial, we are in a position to find out if the health benefits that we have seen in animals can be reproduced in people," says Brenner, who also is co-director of the Obesity Research and Education Initiative, professor of internal medicine, and a member of the Fraternal Order of Eagles Diabetes Research Center at the UI.

Protecting the ozone layer is delivering vast health benefits

Montreal Protocol will spare Americans from 443 million skin cancer cases

National Center for Atmospheric Research, October 7, 2021

An international agreement to protect the ozone layer is expected to prevent 443 million cases of skin cancer and 63 million cataract cases for people born in the United States through the end of this century, according to new research.

The research team, by scientists at the National Center for Atmospheric Research (NCAR), ICF Consulting, and U.S. Environmental Protection Agency (EPA), focused on the far-reaching impacts of a landmark 1987 treaty known as the Montreal Protocol and later amendments that substantially strengthened it. The agreement phased out the use of chemicals such as chlorofluorocarbons (CFCs) that destroy ozone in the stratosphere.

Stratospheric ozone shields the planet from harmful levels of the Sun’s ultraviolet (UV) radiation, protecting life on Earth.

To measure the long-term effects of the Montreal Protocol, the scientists developed a computer modeling approach that enabled them to look to both the past and the future by simulating the treaty’s impact on Americans born between 1890 and 2100. The modeling revealed the treaty’s effect on stratospheric ozone, the associated reductions in ultraviolet radiation, and the resulting health benefits. 

In addition to the number of skin cancer and cataract cases that were avoided, the study also showed that the treaty, as most recently amended, will prevent approximately 2.3 million skin cancer deaths in the U.S.

“It’s very encouraging,” said NCAR scientist Julia Lee-Taylor, a co-author of the study. “It shows that, given the will, the nations of the world can come together to solve global environmental problems.”

The study, funded by the EPA, was published in ACS Earth and Space Chemistry. NCAR is sponsored by the National Science Foundation.

Mounting concerns over the ozone layer

Scientists in the 1970s began highlighting the threat to the ozone layer when they found that CFCs, used as refrigerants and in other applications, release chlorine atoms in the stratosphere that set off chemical reactions that destroy ozone. Concerns mounted the following decade with the discovery of an Antarctic ozone hole.

The loss of stratospheric ozone would be catastrophic, as high levels of UV radiation have been linked to certain types of skin cancer, cataracts, and immunological disorders. The ozone layer also protects terrestrial and aquatic ecosystems, as well as agriculture.

Policy makers responded to the threat with the 1987 Montreal Protocol on Substances that Deplete the Ozone Layer, in which nations agreed to curtail the use of certain ozone-destroying substances. Subsequent amendments strengthened the treaty by expanding the list of ozone-destroying substances (such as halons and hydrochlorofluorocarbons, or HCFCs) and accelerating the timeline for phasing out their use. The amendments were based on Input from the scientific community, including a number of NCAR scientists, that were summarized in quadrennial Ozone Assessment reports.

To quantify the impacts of the treaty, the research team built a model known as the Atmospheric and Health Effects Framework. This model, which draws on various data sources about ozone, public health, and population demographics, consists of five computational steps. These simulate past and future emissions of ozone-destroying substances, the impacts of those substances on stratospheric ozone, the resulting changes in ground-level UV radiation, the U.S. population’s exposure to UV radiation, and the incidence and mortality of health effects resulting from the exposure.

The results showed UV radiation levels returning to 1980 levels by the mid-2040s under the amended treaty. In contrast, UV levels would have continued to increase throughout this century if the treaty had not been amended, and they would have soared far higher without any treaty at all. 

Even with the amendments, the simulations show excess cases of cataracts and various types of skin cancer beginning to occur with the onset of ozone depletion and peaking decades later as the population exposed to the highest UV levels ages. Those born between 1900 and 2040 experience heightened cases of skin cancer and cataracts, with the worst health outcomes affecting those born between about 1950 and 2000.

However, the health impacts would have been far more severe without the treaty, with cases of skin cancer and cataracts rising at an increasingly rapid rate through the century. 

“We peeled away from disaster,” Lee-Taylor said. “What is eye popping is what would have happened by the end of this century if not for the Montreal Protocol. By 2080, the amount of UV has tripled. After that, our calculations for the health impacts start to break down because we’re getting so far into conditions that have never been seen before.”

The research team also found that more than half the treaty’s health benefits could be traced to the later amendments rather than the original 1987 Montreal Protocol. Overall, the treaty prevented more than 99% of potential health impacts that would have otherwise occurred from ozone destruction. This showed the importance of the treaty’s flexibility in adjusting to evolving scientific knowledge, the authors said.

The researchers focused on the U.S. because of ready access to health data and population projections. Lee-Taylor said that the specific health outcomes in other countries may vary, but the overall trends would be similar.

“The treaty had broad global benefits,” she said.

What is Boron?

The trace mineral boron provides profound anti-cancer effects, in addition to maintaining stronger bones.

Life Extension, September 2021

Boron is a trace mineral found in the earth’s crust and in water. Its importance in human health has been underestimated.

Boron has been shown to have actions against specific types of malignancies, such as:

• Cervical cancer: The country Turkey has an extremely low incidence of cervical cancer, and scientists partially attribute this to its boron-rich soil.1 When comparing women who live in boron-rich regions versus boron-poor regions of Turkey, not a single woman living in the boron-rich regions had any indication of cervical cancer.2(The mean dietary intake of boron for women in this group was 8.41 mg/day.) 
  Boron interferes with the life cycle of the human papillomavirus (HPV), which is a contributing factor in approximately 95% of all cervical cancers.1 
  Considering that HPV viruses are increasingly implicated in head and neck cancers,3,4 supplementation with this ultra-low-cost mineral could have significant benefits in protecting against this malignancy that is increasing in prevalence.
• Lung cancer: A study conducted at the University of Texas MD Anderson Cancer Center between 1995 and 2005 found that increased boron intake was associated with a lower risk of lung cancer in postmenopausal women who were taking hormone replacement therapy.
• Prostate cancer: Studies point to boron’s ability to inhibit the growth and spread of prostate cancer cells. 
  In one study, when mice were exposed to boric acid, their tumors shrank by as much as 38%.6 One analysis found that increased dietary boron intake was associated with a decreased risk of prostate cancer.7

Several human and animal studies have confirmed the important connection between boron and bone health.

Boron prevents calcium loss,8 while also alleviating the bone problems associated with magnesium and vitamin D deficiency.9 All of these nutrients help maintain bone density.

A study in female rats revealed the harmful effects a deficiency in boron has on bones, including:10

• Decreased bone volume fraction, a measure of bone strength,
• Decreased thickness of the bone’s spongy inner layer, and
• Decreased maximum force needed to break the femur.

And in a study of post-menopausal women, supplementation with3 mg of boron per day prevented calcium loss and bone demineralization by reducing urinary excretion of both calcium and magnesium.8

In addition to its bone and anti-cancer benefits, there are nine additional reasons boron is an important trace mineral vital for health and longevity. It has been shown to:1

1. Greatly improve wound healing,
2. Beneficially impact the body’s use of estrogen, testosterone, and vitamin D,
3. Boost magnesium absorption,
4. Reduce levels of inflammatory biomarkers, such as high-sensitivity C-reactive protein (hs-CRP) and tumor necrosis factor α (TNF-α),
5. Raise levels of antioxidant enzymes, such as superoxide dismutase (SOD), catalase, and glutathione peroxidase,
6. Protect against pesticide-induced oxidative stress and heavy-metal toxicity,
7. Improve the brain’s electrical activity, which may explain its benefits for cognitive performance, and short-term memory in the elderly,
8. Influence the formation and activity of key biomolecules, such as S-adenosyl methionine (SAM-e) and nicotinamide adenine dinucleotide (NAD+), and
9. Potentially help ameliorate the adverse effects of traditional chemotherapeutic agents.

Because the amount of boron varies in the soil, based on geographical location, obtaining enough boron through diet alone can be difficult.

Supplementing with low-cost boron is an effective way to maintain adequate levels of this overlooked micronutrient.

The Gary Null Show - 10.07.21

Natural compound in basil may protect against Alzheimer's disease pathology

University of South Florida, October 5, 2021

Fenchol, a natural compound abundant in some plants including basil, can help protect the brain against Alzheimer's disease pathology, a preclinical study led by University of South Florida Health (USF Health) researchers suggests.

The new study published Oct. 5 in the Frontiers in Aging Neuroscience, discovered a sensing mechanism associated with the gut microbiome that explains how fenchol reduces neurotoxicity in the Alzheimer's brain.

Emerging evidence indicates that short-chain fatty acids (SCFAs)– metabolites produced by beneficial gut bacteria and the primary source of nutrition for cells in your colon—contribute to brain health. The abundance of SCFAs is often reduced in older patients with mild cognitive impairment and Alzheimer's disease, the most common form of dementia. However, how this decline in SCFAs contributes to Alzheimer's disease progression remains largely unknown.

Gut-derived SCFAs that travel through the blood to the brain can bind to and activate free fatty acid receptor 2 (FFAR2), a cell signaling molecule expressed on brain cellscalled neurons.

"Our study is the first to discover that stimulation of the FFAR2 sensing mechanism by these microbial metabolites (SCFAs) can be beneficial in protecting brain cells against toxic accumulation of the amyloid-beta (Aβ) protein associated with Alzheimer's disease," said principal investigator Hariom Yadav, Ph.D., professor of neurosurgery and brain repair at the USF Health Morsani College of Medicine, where he directs the USF Center for Microbiome Research.

One of the two hallmark pathologies of Alzheimer's disease is hardened deposits of Aβ that clump together between nerve cells to form amyloid protein plaques in the brain. The other is neurofibrillary tangles of tau protein inside brain cells. These pathologies contribute to the neuron loss and death that ultimately cause the onset of Alzheimer's, a neurodegenerative disease characterized by loss of memory, thinking skills and other cognitive abilities.

Dr. Yadav and his collaborators delve into molecular mechanisms to explain how interactions between the gut microbiome and the brain might influence brain health and age-related cognitive decline. In this study, Dr. Yadav said, the research team set out to uncover the "previously unknown" function of FFAR2 in the brain.

The researchers first showed that inhibiting the FFAR2 receptor (thus blocking its ability to "sense" SCFAs in the environment outside the neuronal cell and transmit signaling inside the cell) contributes to the abnormal buildup of the Aβ protein causing neurotoxicity linked to Alzheimer's disease.

Then, they performed large-scale virtual screening of more than 144,000 natural compounds to find potential candidates that could mimic the same beneficial effect of microbiota produced SCFAs in activating FFAR2 signaling. Identifying a natural compound alternative to SCFAs to optimally target the FFAR2 receptor on neurons is important, because cells in the gut and other organs consume most of these microbial metabolites before they reach the brain through blood circulation, Dr. Yadav noted.

Dr. Yadav's team narrowed 15 leading compound candidates to the most potent one. Fenchol, a plant-derived compound that gives basil its aromatic scent, was best at binding to the FFAR's active site to stimulate its signaling.

Further experiments in human neuronal cell cultures, as well as Caenorhabditis (C.) elegans (worm) and mouse models of Alzheimer's disease demonstrated that fenchol significantly reduced excess Aβ accumulation and death of neurons by stimulating FFAR2 signaling, the microbiome sensing mechanism. When the researchers more closely examined how fenchol modulates Aβ-induced neurotoxicity, they found that the compound decreased senescent neuronal cells, also known as "zombie" cells, commonly found in brains with Alzheimer's disease pathology.

Zombie cells stop replicating and die a slow death. Meanwhile, Dr. Yadav said, they build up in diseased and aging organs, create a damaging inflammatory environment, and send stress or death signals to neighboring healthy cells, which eventually also change into harmful zombie cells or die.

"Fenchol actually affects the two related mechanisms of senescence and proteolysis," Dr. Yadav said of the intriguing preclinical study finding. "It reduces the formation of half-dead zombie neuronal cells and also increases the degradation of (nonfunctioning) Aβ, so that amyloid protein is cleared from the brain much faster."

Before you start throwing lots of extra basil in your spaghetti sauce or anything else you eat to help stave off dementia, more research is needed—including in humans.

In exploring fenchol as a possible approach for treating or preventing Alzheimer's pathology, the USF Health team will seek answers to several questions. A key one is whether fenchol consumed in basil itself would be more or less bioactive (effective) than isolating and administering the compound in a pill, Dr. Yadav said. "We also want to know whether a potent dose of either basil or fenchol would be a quicker way to get the compound into the brain."

Researchers find sense of purpose associated with better memory

Florida State University, October 6, 2021

Add an improved memory to the list of the many benefits that accompany having a sense of purpose in life.

A new study led by Florida State University researchers showed a link between an individual's sense of purpose and their ability to recall vivid details. The researchers found that while both a sense of purpose and cognitive function made memories easier to recall, only a sense of purpose bestowed the benefits of vividness and coherence.

The study, which focused on memories related to the COVID-19 pandemic, was published in the journal Memory.

"Personal memories serve really important functions in everyday life," said Angelina Sutin, a professor in the College of Medicine and the paper's lead author. "They help us to set goals, control emotions and build intimacy with others. We also know people with a greater sense of purpose perform better on objective memory tests, like remembering a list of words. We were interested in whether purpose was also associated with the quality of memories of important personal experiences because such qualities may be one reason why purpose is associated with better mental and physical health."

Nearly 800 study participants reported on their sense of purpose and completed tasks that measured their cognitive processing speed in January and February 2020, before the ongoing coronavirus pandemic took hold in the U.S. Researchers then measured participants' ability to retrieve and describe personal memories about the pandemic in July 2020, several months into the public health crisis.

Participants with a stronger sense of purpose in life reported that their memories were more accessible, coherent and vivid than participants with less purpose. Those with a higher sense of purpose also reported many sensory details, spoke about their memories more from a first-person perspective and reported more positive feeling and less negative feeling when asked to retrieve a memory.

The researchers also found that depressive symptoms had little effect on the ability to recall vivid details in memories, suggesting that the connection between life purpose and memory recall is not due to the fewer depressive symptoms among individuals higher in purpose.

Purpose in life has been consistently associated with better episodic memory, such as the number of words retrieved correctly on a memory task. This latest research expands on those connections to memory by showing a correlation between purpose and the richness of personal memory.

"We chose to measure the ability to recall memories associated with the COVID-19 pandemic because the pandemic is an event that touched everyone, but there has been a wide range of experiences and reactions to it that should be apparent in memories," said co-author Martina Luchetti, an assistant professor in the College of Medicine.

Along with the association with better memory, previous research has found other numerous benefits connected with having a sense of purpose, from a lower risk of death to better physical and mental health.

"Memories help people to sustain their well-being, social connections and cognitive health," said co-author Antonio Terracciano, a professor in the College of Medicine. "This research gives us more insight into the connections between a sense of purpose and the richness of personal memories. The vividness of those memories and how they fit into a coherent narrative may be one pathway through which purpose leads to these better outcomes.

Vitamin D protects against severe asthma attacks

Queen Mary University of London, October 3, 2021

Taking oral vitamin D supplements in addition to standard asthma medication could halve the risk of asthma attacks requiring hospital attendance, according to research led by Queen Mary University of London (QMUL).

Asthma affects more than 300 million people worldwide and is estimated to cause almost 400,000 deaths annually. Asthma deaths arise primarily during episodes of acute worsening of symptoms, known as attacks or 'exacerbations', which are commonly triggered by viral upper respiratory infections.

Vitamin D is thought to protect against such attacks by boosting immune responses to respiratory viruses and dampening down harmful airway inflammation.

The new study, funded by the National Institute for Health Research, and published in The Lancet Respiratory Medicine, collated and analysed the individual data from 955 participants in seven randomised controlled trials, which tested the use of vitamin D supplements.

Overall, the researchers found that vitamin D supplementation resulted in:

• a 30 per cent reduction in the rate of asthma attacks requiring treatment with steroid tablets or injections - from 0.43 events per person per year to 0.30.
• a 50 per cent reduction in the risk of experiencing at least one asthma attack requiring Accident and Emergency Department attendance and/or hospitalisation - from 6 per cent of people experiencing such an event to 3 per cent.

Vitamin D supplementation was found to be safe at the doses administered. No instances of excessively high calcium levels or renal stones were seen, and serious adverse events were evenly distributed between participants taking vitamin D and those on placebo.

Lead researcher Professor Adrian Martineau said: "These results add to the ever growing body of evidence that vitamin D can support immune function as well as bone health. On average, three people in the UK die from asthma attacks every day. Vitamin D is safe to take and relatively inexpensive so supplementation represents a potentially cost-effective strategy to reduce this problem."

The team's use of individual participant data also allowed them to query the extent to which different groups respond to vitamin D supplementation, in more detail than previous studies.

In particular, vitamin D supplementation was found to have a strong and statistically-significant protective effect in participants who had low vitamin D levels to start with. These participants saw a 55 per cent reduction in the rate of asthma exacerbations requiring treatment with steroid tablets or injections - from 0.42 events per person per year to 0.19.

However, due to relatively small numbers of patients within sub-groups, the researchers caution that they did not find definitive evidence to show that effects of vitamin D supplementation differ according to baseline vitamin D status.

Professor Hywel Williams, Director of the NIHR Health Technology Assessment Programme, said: "The results of this NIHR-funded study brings together evidence from several other studies from over the world and is an important contribution to reducing uncertainties on whether Vitamin D is helpful for asthma - a common condition that impacts on many thousands of people worldwide."

Dr David Jolliffe from QMUL, first author on the paper, added: "Our results are largely based on data from adults with mild to moderate asthma: children and adults with severe asthma were relatively under-represented in the dataset, so our findings cannot necessarily be generalised to these patient groups at this stage. Further clinical trials are on-going internationally, and we hope to include data from them in a future analysis to determine whether the promise of today's results is confirmed in an even larger and more diverse group of patients."

Study Shows Lifestyle Choices Have Significant Impact on Multiple Chronic Conditions, Significant Implications For Reducing Costs

Yale University,  October 05, 2021

In a study published in the Journal of Preventive Medicine, Adams and colleagues showed a linear association between a number of modifiable risk factors and multiple chronic conditions, making those modifications a key to health care cost savings and to preventing a wide range of conditions.

The data analyzed for the study, https://authors.elsevier.com/a/1VpFeKt2pmc9H, were from the publicly available 2013 Behavioral Risk Factor Surveillance System and included 483,865 non-institutionalized US adults ages 18 years old or older. Chronic conditions included asthma, arthritis, heart disease, stroke, chronic obstructive pulmonary disease (COPD), cognitive impairment, cancer other than skin, and kidney disease. Risk factors included obesity, current smoking, sedentary lifestyle, inadequate fruit and vegetable consumption and sleeping other than seven to eight hours, while depression, hypertension, high cholesterol, and diabetes were considered in each category.

Previous research by Thorpe and colleagues had estimated that the care of adults with four or more chronic conditions (17.1% of all adults in the study) is responsible for 77.6% of all health care costs in the U.S. today.

The potential savings by reducing just two risk factors (diabetes and hypertension) and their related comorbidity was estimated previously by Ormond and colleagues at $9 billion annually over one to two years and closer to $25 billion a year after 5 years or more, factoring in possible complications.

True Health Initiative founder, at Yale University  Director and study co-author David L. Katz, MD, MPH, FACLM, pointed out that in addition to costs, another implication of the study results is an individual's access to healthcare if they have one or more of the chronic conditions.

"Although insurers decide what qualifies as a pre-existing condition, all the chronic conditions used in this study except cognitive impairment are commonly included," he said. "Individuals with a pre-existing condition could be denied coverage or face higher premiums. While having a pre-existing condition might not affect coverage for adults eligible for Medicare, over half of all adults with multiple chronic conditions are ages 18 to 64 years."

American College of Lifestyle Medicine President George Guthrie, MD, MPH, FACLM, said the study confirms the necessity for addressing the root cause of chronic conditions.

"The evidence shows that the risks for chronic disease are rooted in lifestyle choices," he said. "More than ever, it is important to emphasize lifestyle medicine as the first treatment option for preventing, treating, and in some cases, reversing the cause of chronic conditions. If we can help people with chronic conditions, we can add years to their life and life to their years, as well as lower the ever-increasing costs of healthcare for everyone."

Physical athletes' visual skills prove sharper than action video game players

University of Waterloo (Canada), October 7, 2021

Athletes still have the edge over action video gamers when it comes to dynamic visual skills, a new study from the University of Waterloo shows.

For an athlete, having strong visual skills can be the difference between delivering a peak performance and achieving average results.

"Athletes involved in sports with a high-level of movement—like soccer, football, or baseball—often score higher on dynamic visual acuity tests than non-athletes," said Dr. Kristine Dalton of Waterloo's School of Optometry & Vision Science. "Our research team wanted to investigate if action video gamers—who, like e-sport athletes, are regularly immersed in a dynamic, fast-paced 2D video environment for large periods of time—would also show superior levels of dynamic visual acuity on par with athletes competing in physical sport."

While visual acuity (clarity or sharpness of vision) is most often measured under static conditions during annual check-ups with an optometrist, research shows that testing dynamic visual acuity is a more effective measure of a person's ability to see moving objects clearly—a baseline skill necessary for success in physical and e-sports alike. 

Using a dynamic visual acuity skills-test designed and validated at the University of Waterloo, researchers discovered that while physical athletes score highly on dynamic visual acuity tests as expected, action video game players tested closer to non-athletes. 

"Ultimately, athletes showed a stronger ability to identify smaller moving targets, which suggests visual processing differences exist between them and our video game players," said Alan Yee, a Ph.D. candidate in vision science. All participants were matched based on their level of static visual acuity and refractive error, distinguishing dynamic visual acuity as the varying factor on their test performance.

These findings are also important for sports vision training centers that have been exploring the idea of developing video game-based training programs to help athletes elevate their performance.

"Our findings show there is still a benefit to training in a 3D environment," said Dalton. "For athletes looking to develop stronger visual skills, the broader visual field and depth perception that come with physical training may be crucial to improving their dynamic visual acuity—and ultimately, their sport performance." 

The study, Athletes demonstrate superior visual dynamic visual acuity, authored by Waterloo's School of Optometry & Vision Science's Dalton, Yee, Dr. Elizabeth Irving and Dr. Ben Thompson, was recently published in the journal Optometry and Vision Science.

Probiotic Akkermansia muciniphila and environmental enrichment reverse cognitive impairment associated with high-fat high-cholesterol consumption

University of Oviedo (Spain), September 8, 2021

Nonalcoholic steatohepatitis (NASH) is one of the most prevalent diseases globally. A high-fat, high-cholesterol (HFHC) diet leads to an early NASH model. It has been suggested that gut microbiota mediates the effects of diet through the microbiota–gut–brain axis, modifying the host’s brain metabolism and disrupting cognition. Here, we target NASH-induced cognitive damage by testing the impact of environmental enrichment (EE) and the administration of either Lacticaseibacillus rhamnosus GG (LGG) or Akkermansia muciniphila CIP107961 (AKK). EE and AKK, but not LGG, reverse the HFHC-induced cognitive dysfunction, including impaired spatial working memory and novel object recognition; however, whereas AKK restores brain metabolism, EE results in an overall decrease. Moreover, AKK and LGG did not induce major rearrangements in the intestinal microbiota, with only slight changes in bacterial composition and diversity, whereas EE led to an increase in Firmicutes and Verrucomicrobia members. Our findings illustrate the interplay between gut microbiota, the host’s brain energy metabolism, and cognition. In addition, the findings suggest intervention strategies, such as the administration of AKK, for the management of the cognitive dysfunction related to NASH.

In this study, we described cognitive, brain metabolism, and microbiota alterations associated with high-fat and high-cholesterol consumption. In addition, we clearly showed that environmental enrichment and A. muciniphila CIP107961 restore cognitive dysfunction. Furthermore, we revealed that cognitive improvement is associated with differential effects of environmental enrichment and this strain of A. muciniphila on brain metabolism and gut microbiota. Finally, we discovered that restored cognitive function was associated with the administration of A. muciniphila CIP107961, but not L. rhamnosus GG, which may be clinically relevant when selecting probiotics for treating HFHC-derived pathologies.

In conclusion, the microbiota and cognition are intimately connected through the gut–brain axis, and in HFHC pathologies they can be influenced by environmental enrichment and A. muciniphila CIP107961 administration. Cognitive improvement was accompanied by changes in brain metabolic activity and gut microbial composition analysis, pointing to specific microbiota targets for intervention in diet-induced pathologies. However, some mechanisms other than major changes in microbiota composition and the combined effect of environmental enrichment and A. muciniphila administration, which we identified in this study, may also be biologically relevant and will need to be investigated in future studies due to their relative contributions to the selection of effective treatments for patients.

The Gary Null Show - 10.06.21

Gary takes on the real issues that the mainstream media is afraid to tackle. Tune in to find out the latest about health news, healing, politics, and the economy.

The Gary Null Show - 10.05.21

The Gary Null Show - 10.04.21

Gary takes on the real issues that the mainstream media is afraid to tackle. Tune in to find out the latest about health news, healing, politics, and the economy.

The Gary Null Show -10.01.21

Investigating the anti-hypertensive effects of pumpkin seed oil

Marymount University and University of Guilan (Iran), September 29, 2021

In a study, researchers from Iran and the U.S. found that pumpkin seed oil can potentially treat hypertension in postmenopausal women. Their report was published in Complementary Therapies in Clinical Practice.

• Postmenopausal women are more likely to develop hypertension than men of the same age.
• In vivo studies reveal that pumpkin seed oil has anti-hypertensive activity.
• The team investigated the effects of pumpkin seed oil supplementation on vascular function and heart rate variability in postmenopausal women with elevated blood pressure.
• Participants were assigned to take either a pumpkin seed oil supplement or a placebo for the six-week study. Those in the experimental group took 3 grams of pumpkin seed oil every day.
• Brachial and central blood pressure, wave reflection (augmentation index, AIx), arterial stiffness (SI) and various HRV parameters were measured at baseline and at the end of the study.
• Those who took pumpkin seed oil had significantly lower AIx, brachial and systolic blood pressure after treatment. SI and HRV parameters remained unchanged for the treatment group and the placebo group at the end of the study.

In sum, taking pumpkin seed oil may improve arterial hemodynamics in postmenopausal women.

Health benefits of evening classes revealed

Oxford University, September 20, 2021 

Those with a taste for adult education classes have long known it, but now Oxford University scientists have confirmed that taking part in the weekly sessions can boost wellbeing – regardless of the subject studied.

In partnership with the Workers' Educational Association (WEA), the largest voluntary sector provider of adult education in England and Scotland, a team from Oxford's department of experimental psychology studied attendees at seven separate day-time adult education classes. Their findings are published in a series of papers.

Each class took place over seven months and included a break in the middle. Attendees completed questionnaires before and after their class three times over the seven months: at the beginning of their courses, after 3 months, and at the end of the seven months. Participants were involved in one of three activities: singing, crafts or creative writing.

Overall, attendees at all seven classes had improved mental and physical health and reported more satisfaction with their lives at the end of their courses.

Dr Eiluned Pearce led the research. She said: 'The students reported benefits including increased self-confidence, a greater feeling of control over their lives and more willingness to take on new challenges. Some said the classes made them more motivated to be more active, despite the classes not specifically involving physical activity.

'Participants also said that the classes broadened their networks of friends and gave them an increased sense of belonging. We also found that the more someone felt part of their group, the more their health and wellbeing improved.'

An intriguing finding was in the singing and creative writing classes. Building on the results of an earlier paper from the same study, which found that people in singing classes felt closer to their group more quickly than those in the other classes, the team looked at how relationships formed between individuals in the classes.

Each person was asked to name those other people in the class whose name they could remember, whether or not they felt connected to each person they named, and whether they had talked to that person during class.

Dr Pearce said: 'The results showed that those in the singing and creative writing groups built up relationships with other individuals more quickly than the crafters, and singers felt more connected to the class as a whole more quickly than both the other groups.

'While this confirms our earlier finding that singing has an 'ice-breaker effect' compared to other activities, it shows that other activities may enable people to increase their social networks just as much, even if it takes them longer to feel connected to their group as a whole.'

Co-author Dr Jacques Launay adds: 'While much of our previous work has demonstrated the importance of music, it is likely that the most socially bonding activities are always those that are personally chosen and enjoyed. This research adds to growing support for the relevance of creative activities in creating happy communities and improving health and well-being, with consequent benefits for public services and society.'

Dr Pádraig Mac Carron, Dr Anna Machin and Professor Robin Dunbar were also involved in the research.

Howard Croft, WEA Regional Education Manager, said: 'The findings reiterate the feedback that we have had from our students over the years: learning is a fantastic way to boost your self-esteem and confidence. Also of note, is its therapeutic effect. For many students, creative courses are a means of finding a new outlet for expressing their feelings. This can be of immense help during times of personal difficulty or emotional upheaval, such as divorce or bereavement. Simply going to a course can offer much-needed respite.

'For others, learning can be an opportunity to reignite a former passion. This could be anything from a subject which you enjoyed at school to an area which you are interested in. Whatever your reason, there are so many benefits to be gained by signing up to a course.'

Want to live forever? Theoretically, you could, study says

Swiss Federal Institute of Technology, September 29, 2021

Humans can probably live to at least 130, and possibly well beyond, though the chances of reaching such super old age remain vanishingly small, according to new research.

The outer limit of the human lifespan has long been hotly debated, with recent studies making the case we could live up to 150 years, or arguing that there is no maximum theoretical age for humans.

The new research, published Wednesday in the Royal Society Open Science journal, wades into the debate by analyzing new data on supercentenarians—people aged 110 or more—and semi-supercentenarians, aged 105 or more.

While the risk of death generally increases throughout our lifetime, the researchers' analysis shows that risk eventually plateaus and remains constant at approximately 50-50.

"Beyond age 110 one can think of living another year as being almost like flipping a fair coin," said Anthony Davison, a professor of statistics at the Swiss Federal Institute of Technology in Lausanne (EPFL), who led the research.

"If it comes up heads, then you live to your next birthday, and if not, then you will die at some point within the next year," he told AFP.

Based on the data available so far, it seems likely that humans can live until at least 130, but extrapolating from the findings "would imply that there is no limit to the human lifespan," the research concludes.

The conclusions match similar statistical analyses done on datasets of the very elderly.

"But this study strengthens those conclusions and makes them more precise because more data are now available," Davison said.

The first dataset the team studied is newly released material from the International Database on Longevity, which covers more than 1,100 supercentenarians from 13 countries.

The second is from Italy on every person who was at least 105 between January 2009 and December 2015.

'One in a million'

The work involves extrapolating from existing data, but Davison said that was a logical approach.

"Any study of extreme old age, whether statistical or biological, will involve extrapolation," he said.

"We were able to show that if a limit below 130 years exists, we should have been able to detect it by now using the data now available," he added.

Still, just because humans can theoretically reach 130 or beyond, doesn't mean we're likely to see it anytime soon.

For a start, the analysis is based on people who have already achieved the relatively rare feat of making it to well over 100.

And even at age 110, your chances of making it to 130 are "about one in a million... not impossible but very unlikely," said Davison.

He thinks we could see people reaching 130 within the century, as more people make it to supercentenarian status, increasing the chances of one becoming that one in a million.

"But in the absence of major medical and social advances, ages much over this are highly unlikely ever to be observed," he added.

For now, the oldest person on record is Frenchwoman Jeanne Calment, who died in 1997 at the confirmed age of 122.

Her true age was the subject of some controversy, with claims of a possible fraud, but in 2019 several experts said a review of the evidence confirmed her age.

Other pretenders to the throne of oldest person ever have a long way to go. The oldest verified living person in the world is Japan's Kane Tanaka, a comparatively youthful 118.

Psychological treatment shown to yield strong, lasting pain relief, alter brain networks

University of Colorado, September 29, 2021

Rethinking what causes pain and how great of a threat it is can provide chronic pain patients with lasting relief and alter brain networks associated with pain processing, according to new University of Colorado Boulder-led research.

The study, published Sept. 29 in JAMA Psychiatry, found that two-thirds of chronic back pain patients who underwent a four-week psychological treatment called Pain Reprocessing Therapy (PRT) were pain-free or nearly pain-free post-treatment. And most maintained relief for one year.

The findings provide some of the strongest evidence yet that a psychological treatmentcan provide potent and durable relief for chronic pain, which afflicts one in five Americans.

"For a long time we have thought that chronic pain is due primarily to problems in the body, and most treatments to date have targeted that," said lead author Yoni Ashar, who conducted the study while earning his Ph.D. in the Department of Psychology and Neuroscience at CU Boulder. "This treatment is based on the premise that the brain can generate pain in the absence of injury or after an injury has healed, and that people can unlearn that pain. Our study shows it works."

Misfiring neural pathways

Approximately 85% of people with chronic back pain have what is known as "primary pain," meaning tests are unable to identify a clear bodily source, such as tissue damage.

Misfiring neural pathways are at least partially to blame: Different brain regions—including those associated with reward and fear—activate more during episodes of chronic pain than acute pain, studies show. And among chronic pain patients, certain neural networks are sensitized to overreact to even mild stimuli.

If pain is a warning signal that something is wrong with the body, primary chronic pain, Ashar said, is "like a false alarm stuck in the 'on' position."

PRT seeks to turn off the alarm.

"The idea is that by thinking about the pain as safe rather than threatening, patients can alter the brain networks reinforcing the pain, and neutralize it," said Ashar, now a postdoctoral researcher at Weill Cornell Medicine.or the randomized controlled trial, Ashar and senior author Tor Wager, now the Diana L. Taylor Distinguished Professor in Neuroscience at Dartmouth College, recruited 151 men and women who had back pain for at least six months at an intensity of at least four on a scale of zero to 10.

Those in the treatment group completed an assessment followed by eight one-hour sessions of PRT, a technique developed by Los Angeles-based pain psychologist Alan Gordon. The goal: To educate the patient about the role of the brain in generating chronic pain; to help them reappraise their pain as they engage in movements they'd been afraid to do; and to help them address emotions that may exacerbate their pain. 

Pain is not 'all in your head'

"This isn't suggesting that your pain is not real or that it's 'all in your head'," stressed Wager, noting that changes to neural pathways in the brain can linger long after an injury is gone, reinforced by such associations. "What it means is that if the causes are in the brain, the solutions may be there, too."

Before and after treatment, participants also underwent functional magnetic resonance imaging (fMRI) scans to measure how their brains reacted to a mild pain stimulus.

After treatment, 66% of patients in the treatment group were pain-free or nearly pain-free compared to 20% of the placebo group and 10% of the no-treatment group.

"The magnitude and durability of pain reductions we saw are very rarely observed in chronic pain treatment trials," Ashar said, noting that opioids have yielded only moderate and short-term relief in many trials.

And when people in the PRT group were exposed to pain in the scanner post-treatment, brain regions associated with pain processing—including the anterior insula and anterior midcingulate —had quieted significantly.

The authors stress that the treatment is not intended for "secondary pain"—that rooted in acute injury or disease.

The study focused specifically on PRT for chronic back pain, so future, larger studies are needed to determine if it would yeild similar results for other types of chronic pain. 

Meanwhile, other similar brain-centered techniques are already ememrging among physical therapists and other clinicians who treat pain.

"This study suggests a fundamentally new way to think about both the causes of chronic back pain for many people and the tools that are available to treat that pain," said co-author Sona Dimidjian, professor of psychology and neuroscience and director of the Renee Crown Wellness Institute at CU Boulder. " It provides a potentially powerful option for people who want to live free or nearly free of pain."

Citicoline (CDP-choline) and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial 

Kyowa Hakko Bio (Japan), September 2021

Supplementation of citicoline (CDP-choline), a naturally occurring mononucleotide, has shown beneficial effects on memory function and behavior in populations with a wide range of impairments. However, few studies have investigated its effect in healthy older populations.

Objective

The objective of this study was to investigate the effects of citicoline, on memory in healthy elderly populations with age-associated memory impairment (AAMI).

Methods

A total of 100 healthy men and women aged between 50 and 85 y with AAMI participated in this randomized, double-blind, placebo-controlled trial. Participants were randomized to receive placebo (n = 51) or citicoline (n = 49; 500 mg/d) for 12 wk. Memory function was assessed at baseline and end of the intervention (12 wk) using computerized tests (Cambridge Brain Sciences, Ontario, Canada). Safety measurements included adverse events query, body weight, blood pressure, and hematology and metabolic panel. Intent-to-treat analysis was conducted using ANCOVA for the primary and secondary outcome variables with Bonferroni correction for multiple comparisons.

Results

A total of 99 out of 100 participants completed the study in its entirety. After the 12-wk intervention, participants supplemented with citicoline showed significantly greater improvements in secondary outcomes of episodic memory (assessed by the Paired Associate test), compared with those on placebo (mean: 0.15 vs. 0.06, respectively, P = 0.0025). Composite memory (secondary outcome), calculated using the scores of 4 memory tests, also significantly improved to a greater extent following citicoline supplementation (mean: 3.78) compared with placebo (mean: 0.72, P = 0.0052).

Conclusions

Dietary supplementation of citicoline for 12 wk improved overall memory performance, especially episodic memory, in healthy older males and females with AAMI. The findings suggest that regular consumption of citicoline may be safe and potentially beneficial against memory loss due to aging. 

Sleep may strengthen long-term memories in the immune system

University of Tuebingen (Germany) September 29, 2021

More than a century ago, scientists demonstrated that sleep supports the retention of memories of facts and events. Later studies have shown that slow-wave sleep, often referred to as deep sleep, is important for transforming fragile, recently formed memories into stable, long-term memories. Now, in an Opinion article published  in Trends in Neurosciences, part of a special issue on Neuroimmunology, researchers propose that deep sleep may also strengthen immunological memories of previously encountered pathogens.

"While it has been known for a long time that sleep supports long-term memoryformation in the psychological domain, the idea that long-term memory formation is a function of sleep effective in all organismic systems is in our view entirely new," says senior author Jan Born of the University of Tuebingen. "We consider our approach toward a unifying concept of biological long-term memory formation, in which sleep plays a critical role, a new development in sleep research and memory research."

The immune system "remembers" an encounter with a bacteria or virus by collecting fragments from the bug to create memory T cells, which last for months or years and help the body recognize a previous infection and quickly respond. These memory T cells appear to abstract "gist information" about the pathogens, as only T cells that store information about the tiniest fragments ever elicit a response. The selection of gist information allows memory T cells to detect new pathogens that are similar, but not identical, to previously encountered bacteria or viruses.

Studies in humans have shown that long-term increases in memory T cells are associated with deep slow-wave sleep on the nights after vaccination. Taken together, the findings support the view that slow-wave sleep contributes to the formation of long-term memories of abstract, generalized information, which leads to adaptive behavioral and immunological responses. The obvious implication is that sleep deprivation could put your body at risk.

"If we didn't sleep, then the immune system might focus on the wrong parts of the pathogen," Born says. "For example, many viruses can easily mutate some parts of their proteins to escape from immune responses. If too few antigen-recognizing cells [the cells that present the fragments to T cells] are available, then they might all be needed to fight off the pathogen. In addition to this, there is evidence that the hormones released during sleep benefit the crosstalk between antigen-presenting and antigen-recognizing cells, and some of these important hormones could be lacking without sleep."

Born says that future research should examine what information is selected during sleep for storage in long-term memory, and how this selection is achieved. In the end, this research could have important clinical implications.

"In order to design effective vaccines against HIV, malaria, and tuberculosis, which are based on immunological memory, the correct memory model must be available," Born says. "It is our hope that by comparing the concepts of neuronal and immunological memory, a model of immunological memory can be developed which integrates the available experimental data and serves as a helpful basis for vaccine development."

Standardized astragalus extract for attenuation of the immunosuppression induced by strenuous physical exercise: randomized controlled trial

University of Physical Sciences (Poland), September 3, 2021

This paper aimed to verify how a supplementation of rower’s diet with Astragalus Membranaceus Root (AMR) modulated their immune system response to maximal physical exertion.

Methods

The double-blind study included 18 members of the Polish Rowing Team assigned to the supplemented group (n = 10), and the placebo group (n = 8). The participants performed a 2000 m test on a rowing ergometer at the beginning and at the end of the six-week of intensive training camp during which the supplemented group received 500 mg of AMR. Blood samples were obtained prior to, 1 min after completing, and 24 h after the exertion test. The levels of interleukin 2 (IL2), interleukin 4 (IL4), interleukin 10 (IL10), interferon ɤ (IFN-ɣ), and lactic acid were determined. Subpopulations of T regulatory lymphocytes [CD4+/CD25+/CD127−] (Treg), cytotoxic lymphocytes [CD8+/TCRαβ+] (CTL), natural killer cells [CD3−/CD16+/CD56+] (NK), and TCRδγ-positive cells (Tδγ) were determined with flow cytometry.

Results

After the camp, the initial NK and Treg levels sustained at the baseline, while Tδγ counts increased relative to the levels in the placebo group. In the supplemented subgroup, a decrease in IL2 level in reaction to maximal exertion clearly deepened while the change in IL-2/IL-10 level induced by the recovery after this exertion clearly increased, relative to the changes in the placebo group.

Conclusions

AMR restored the immunological balance in strenuously trained athletes through a stabilization of NK and Treg cells with a positive trend in Tδγ towards Th1 response during restitution by cytokine IL2 modulation.